

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number
WO 01/14416 A2

- (51) International Patent Classification⁷: C07K 14/00
- (21) International Application Number: PCT/US00/22932
- (22) International Filing Date: 21 August 2000 (21.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/150,728 25 August 1999 (25.08.1999) US
60/210,143 7 June 2000 (07.06.2000) US
- (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): NEEPER, Michael, P. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). MCCLEMENTS, William, L. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: SYNTHETIC HUMAN PAPILLOMAVIRUS GENES

Comparison of protein expression of native and synthetic HPV16 L1 genes




FIGURE 9 shows the results of immunoblot analysis of lysates of 293 cells transiently-transfected with native (lanes d, e, f) or synthetic (a, b, c) HPV 16 L1 sequences in the expression vector V1Jns

(57) Abstract: Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.



IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *Without international search report and to be republished upon receipt of that report.*

TITLE OF THE INVENTION

SYNTHETIC HUMAN PAPILLOMAVIRUS GENES

FIELD OF THE INVENTION

5 This invention relates to human papillomavirus (HPV) genes which have been codon-optimized for expression in a human cellular environment, and their use with adenoviral vectors and or plasmid vectors as vaccines.

BACKGROUND OF THE INVENTION

10 Papillomavirus infections occur in a variety of animals, including humans, sheep, dogs, cats, rabbits, snakes, monkeys and cows. Papillomaviruses infect epithelial cells, generally inducing benign epithelial or fibroepithelial tumors at the site of infection. Papillomaviruses are species specific infective agents; a human papillomavirus cannot infect a non-human.

15 Papillomaviruses are small (50-60nm), nonenveloped, icosahedral DNA viruses what encode up to eight early and two late genes. The open reading frames (ORFs) of the virus are designated E1 to E7 and L1 and L2, where "E" denotes early and "L" denotes late. L1 and L2 code for virus capsid proteins. The early genes are associated with functions such as viral replication and cellular transformation.

20 In humans, different HPV types cause distinct diseases, ranging from benign warts (for examples HPV types 1, 2, 3) to highly invasive genital and anal carcinomas (HPV types 16 and 18). At present there is not a satisfactory therapeutic regimen for these diseases.

25 Immunological studies in animals have shown that the production of neutralizing antibodies to papillomavirus antigens prevents infection with the homologous virus. However, development of a vaccine has been hindered by the difficulties associated with culture of the papillomavirus *in vitro*.

30 Vaccination is an effective form of disease prevention and has proven successful against several types of viral infection. However, to date, attempts to generate an effective HPV vaccine have not been entirely successful.

SUMMARY OF THE INVENTION

 This invention relates to oligonucleotides which encode a human papillomavirus (HPV) protein which has been codon-optimized for efficient

expression in a host cell; preferably the oligonucleotides are DNA. In one embodiment, the polynucleotides encode a protein which retains its wild-type amino acid sequence. In an alternate embodiment, the polynucleotides encode a mutated form of a HPV protein which has reduced protein function as compared to wild-type protein, but which maintains immunogenicity. This invention also relates to the mutated HPV proteins so encoded.

In preferred embodiments, the protein is selected from the group consisting of: L1, L2, E1, E2, E4, E5, E6 and E7 proteins. Particularly preferred are L1, L2, E2, and E7 proteins.

Another aspect of this invention is a vector carrying the polynucleotides encoding a codon-optimized HPV protein. Yet another aspect of this invention are host cells containing these vectors.

In a preferred embodiment, the vector is an adenoviral vector. In a particularly preferred embodiment, the adenoviral vector is a vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising:

a) a polynucleotide encoding an HPV protein selected from the group consisting of L1, E1, E2, and E7 proteins or mutant forms thereof, wherein the polynucleotide is codon-optimized for expression in a human host cell; and

b) a promoter operably linked to the polynucleotide.

Another type of vector which is envisioned by this invention is a shuttle plasmid vector comprising a plasmid portion and an adenoviral portion, the adenoviral portion comprising: an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising:

a) a polynucleotide encoding an HPV protein selected from the group consisting of L1, E1, E2, and E7 proteins, wherein the polynucleotide is codon-optimized for expression in a human host cell; and

b) a promoter operably linked to the polynucleotide.

This invention also is directed to plasmid vaccine vectors, which comprise a plasmid portion and an expressible cassette comprising

a) a polynucleotide encoding an HPV protein selected from the group consisting of L1, E1, E2, and E7 proteins, wherein the polynucleotide is codon-optimized for expression in a human host cell; and

b) a promoter operably linked to the polynucleotide.

This invention also relates to vaccine compositions comprising a vector which carries the oligonucleotides to a human host, and allows for expression of the encoded protein. The protein is expressed in an amount sufficient to induce an immune response. In preferred embodiments, the vector is a plasmid vector or an
5 adenoviral vector.

This invention also relates to a method of making a HPV protein comprising expressing in a host cell a synthetic polynucleotide encoding a human papillomavirus (HPV) protein, or mutated form of a HPV protein which has reduced
10 protein function as compared to wild-type protein, but which maintains immunogenicity, the polynucleotide sequence comprising codons optimized for expression in a human host.

BRIEF DESCRIPTION OF THE DRAWINGS

15 FIGURE 1 is the nucleotide sequence of a codon-optimized HPV16 L1 gene (SEQ.ID.NO:1).

FIGURE 2 is the nucleotide sequence of a codon-optimized HPV16 E1 gene (SEQ.ID.NO:2). In this particular sequence, there are further mutations which changes the amino acid sequence of the expressed protein-- the glycine residue at
20 position 428 has been converted to aspartic acid, and the tryptophan residue at position 439 is now arginine.

FIGURE 3 is the nucleotide sequence of a codon-optimized HPV16 E2 gene (SEQ.ID.NO:3). In this particular sequence, the glutamic acid residue at position 39 has been changed to an alanine, and the isoleucine residue at position 73
25 has also been changed to an alanine.

FIGURE 4 is the nucleotide sequence of a codon-optimized HPV16 E7 gene.(SEQ.ID.NO:4). In this particular sequence, the cysteine residue at position 24 has been changed to glycine, and the glutamic acid residue at position 26 has been changed to a glycine.

30 FIGURE 5 is the nucleotide sequence of a codon-optimized HPV6a E7 gene (SEQ.ID.NO:5).

FIGURE 6 is the nucleotide sequence of a codon-optimized HPV18 E7 gene (SEQ.ID.NO:6).

FIGURE 7 is the nucleotide sequence of a codon-optimized HPV6a E2 gene (SEQ.ID.NO:7).

FIGURE 8 is the nucleotide sequence of a codon-optimized HPV18 E2 gene (SEQ.ID.NO:8).

5 FIGURE 9 shows the results of immunoblot analysis of lysates of 293 cells transiently-transfected with native (lanes d, e, f) or synthetic (a, b, c) HPV16 L1 sequences in the expression vector V1Jns.

FIGURE 10 shows the results of immunoblot analysis of lysates of 293 cells transiently-transfected with native or synthetic HPV16 E1 sequences in the
10 expression vector V1Jns. Lanes a and d contain native HPV16 E1 sequences; lanes b and e contain synthetic HPV16 E1, and lane c is a mock-transfected control.

FIGURE 11 shows the results of immunoblot analysis of lysates of 293 cells transiently-transfected with native or synthetic HPV16 E2 sequences in the
15 expression vector V1Jns. Lane a is mock-infected; lane b is lacZ control; lane c contains a synthetic HPV16 E2 isolate #6; lane d contains synthetic HPV16 E2 isolate #11, and lane e has native HPV16 E2.

FIGURE 12 shows the results of immunoblot analysis of lysates of 293 cells transiently-transfected with native or synthetic HPV16 E7 sequences in the
20 expression vector V1Jns. Lane a is mock-infected; lane b is lacZ control; lane c contains synthetic HPV16 E7 isolate #2; lane d is synthetic HPV16 E7 isolate 4; and lane e is native HPV16 E7.

FIGURE 13 shows the results of immunoblot analysis of lysates of 293 cells transiently-transfected with synthetic HPV6a E7 sequences in the expression
25 vector V1Jns. Lanes b and c contain synthetic HPV6a E7 sequences; lane d contains a lacZ control, and lane a is a mock-transfected control.

FIGURE 14 shows the results of immunoblot analysis of lysates of 293 cells transiently-transfected with synthetic HPV18 E7 sequences in the expression
30 vector V1Jns. Lanes b, c, d, and e contain synthetic HPV18 E7 sequences; lane f contains synthetic HPV16 E7 as an antibody control, and lane a is a mock-transfected control.

FIGURE 15 shows the results of immunoblot analysis of lysates of 293 cells transiently-transfected with synthetic HPV6a E2 sequences in the expression
vector V1Jns. Lanes a and b contain synthetic E2 sequences; lane c is a beta-gal control, and lane d is mock-transfected.

FIGURE 16 shows the results of immunoblot analysis of lysates of 293 cells transiently-transfected with synthetic HPV18 E2 sequences in the expression vector V1Jns. Lane a is beta-gal control; lane b is mock transfected; and lanes c and d have synthetic sequences.

5 FIGURE 17 is a table of oligonucleotides (SEQ.ID.NOS:9-32) used to generate synthetic HPV16 L1.

FIGURE 18 is a table of oligonucleotides (SEQ.ID.NOS:33-64) used to generate synthetic HPV16 E1.

10 FIGURE 19 is a table of oligonucleotides (SEQ.ID.NOS:65-84) used to generate synthetic HPV16 E2.

FIGURE 20 is a table of oligonucleotides (SEQ.ID.NOS:85-90) used to generate synthetic HPV16 E7.

FIGURE 21 is a table of oligonucleotides (SEQ.ID.NOS:91-96) used to generate synthetic HPV6a E7.

15 FIGURE 22 is a table of oligonucleotides (SEQ.ID.NOS:97-102) used to generate synthetic HPV18 E7.

FIGURE 23 is a table of oligonucleotides (SEQ.ID.NOS:103-126) used to generate synthetic HPV6a E2.

20 FIGURE 24 is a table of oligonucleotides (SEQ.ID.NOS:127-150) used to generate synthetic HPV18 E2.

FIGURE 25 is a Western blot of JCL-031 cell lysate. Cell lysate was prepared from JCL-031 cells grown in selection medium containing 400 μ g/mL G418. The immunoblot was developed with anti-HPV 16 E2 (goat 248) antisera. Positions of molecular weight markers are indicated.

25 FIGURE 26 shows protection from JCL-031 cell-induced tumor outgrowth. E2 DNA- or control DNA-immunized mice were challenged by subcutaneous injection of 5×10^5 JCL-031 cells into the left inguinal region. Beginning five days after this challenge, all animals were observed at two or three day intervals until four weeks after inoculation. Tumors were detected and monitored
30 by visual inspection, palpation of the inguinal region, and measurement of tumor diameter with calipers.

The term "promoter" as used herein refers to a recognition site on a DNA strand to which the RNA polymerase binds. The promoter forms an initiation

complex with RNA polymerase to initiate and drive transcriptional activity. The complex can be modified by activating sequences termed "enhancers" or inhibiting sequences termed "silencers".

The term "cassette" refers to the sequence of the present invention which contains the nucleic acid sequence which is to be expressed. The cassette is similar in concept to a cassette tape; each cassette has its own sequence. Thus by interchanging the cassette, the vector will express a different sequence. Because of the restrictions sites at the 5' and 3' ends, the cassette can be easily inserted, removed or replaced with another cassette.

The term "vector" refers to some means by which DNA fragments can be introduced into a host organism or host tissue. There are various types of vectors including plasmid, virus (including adenovirus), bacteriophages and cosmids.

The term "effective amount" means sufficient vaccine composition is introduced to produce the adequate levels of the polypeptide, so that an immune response results. One skilled in the art recognizes that this level may vary.

"Synthetic" means that the HPV gene has been modified so that it contains codons which are preferred for human expression. In many cases, the amino acids encoded by the gene remain the same. In some embodiments, the synthetic gene may encode a modified protein.

The term "native" means that the gene contains the DNA sequence as found in occurring in nature. It is a wild type sequence of viral origin.

DETAILED DESCRIPTION OF THE INVENTION

Synthetic DNA molecules encoding various HPV proteins are provided. The codons of the synthetic molecules are designed so as to use the codons preferred by the projected host cell, which is preferred embodiments is a human cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity. The synthetic molecules may be used as an immunogenic composition. This invention provides polynucleotides which, when directly introduced into a vertebrate *in vivo*, including mammals such as primates and humans, induce the expression of encoded proteins within the animal.

The gene encoding a L1, E1, E2 and/or E7 from any serotype HPV can be modified in accordance with this invention. It is preferred that the HPV chosen be

one which is known to cause a pathological condition in humans. For this reason, it is preferred that the HPV gene be selected from the group consisting of: HPV6a, HPV6b, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV68 or variants thereof. The vaccine
5 formulation of this invention may contain a mixture of HPV type protein genes (for example, genes from HPV6, 11, 16 and 18), and/or it may also contain a mixture of protein genes (i.e. L1, E1, E2, and/or E7).

Codon optimization

10 The wild-type sequences for many HPV genes are known. In accordance with this invention, HPV gene segments were converted to sequences having identical translated sequences but with alternative codon usage as defined by Lathe, 1985 "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data: Theoretical and Practical Considerations" *J. Molec. Biol.* 183:1-12, which is
15 hereby incorporated by reference. The methodology may be summarized as follows:

1. Identify placement of codons for proper open reading frame.
2. Compare wild type codon for observed frequency of use by human genes.
3. If codon is not the most commonly employed, replace it with
20 an optimal codon for high expression in human cells.
4. Repeat this procedure until the entire gene segment has been replaced.
5. Inspect new gene sequence for undesired sequences generated by these codon replacements (e.g., "ATTTA" sequences, inadvertent creation of
25 intron splice recognition sites, unwanted restriction enzyme sites, etc.) and substitute codons that eliminate these sequences.
6. Assemble synthetic gene segments and test for improved expression.

30 In accordance with this invention, it has been found that the use of alternative codons encoding the same protein sequence may remove the constraints on expression of HPV proteins by human cells.

These methods were used to create the following synthetic gene segments for various papillomavirus genes creating a gene comprised entirely of codons optimized for high level expression. While the above procedure provides a

summary of our methodology for designing codon-optimized genes for DNA vaccines, it is understood by one skilled in the art that similar vaccine efficacy or increased expression of genes may be achieved by minor variations in the procedure or by minor variations in the sequence.

5 In some embodiments of this invention, alterations have been made (particularly in the E-protein native protein sequences) to reduce or eliminate protein function while preserving immunogenicity. Mutations which decrease enzymatic function are known. Certain alterations were made for purposes of expanding safety margins and/or improving expression yield. These modifications are accomplished
10 by a change in the codon selected to one that is more highly expressed in mammalian cells. In the case of HPV16 E1, for example two mutations were introduced: glycine at amino acid number 482 was changed to aspartic acid by conversion of GGC to GAC; and tryptophan was changed to arginine at position 439 by conversion of TGG to CGC.

15 For HPV16 E2, conversion of glutamic acid at position 39 to alanine and isoleucine at position 73 to alanine by conversion of both codons each to GCC.

 For HPV16 E7, conversion of cysteine at position 24 to glycine and glutamic acid at position 26 to glycine was permitted by alteration of TGC and the GAG respectively both to GGC.

20 The codon-optimized genes are then assembled into an expression cassette which comprises sequences designed to provide for efficient expression of the protein in a human cell. The cassette preferably contains the codon-optimized gene, with related transcriptional and translations control sequences operatively linked to it, such as a promoter, and termination sequences. In a preferred
25 embodiment, the promoter is the cytomegalovirus promoter with the intron A sequence (CMV-intA), although those skilled in the art will recognize that any of a number of other known promoters such as the strong immunoglobulin, or other eukaryotic gene promoters may be used. A preferred transcriptional terminator is the bovine growth hormone terminator, although other known transcriptional terminators
30 may also be used. The combination of CMVintA-BGH terminator is particularly preferred.

 Examples of preferred gene sequences are given in SEQ.ID.NOS: 1-8.

VECTORS

In accordance with this invention, the expression cassette encoding at least one HPV protein is then inserted into a vector. The vector is preferably a plasmid or an adenoviral vector, although linear DNA linked to a promoter, or other
5 vectors, such as adeno-associated virus or a modified vaccinia virus vector may also be used.

If the vector chosen is an adenovirus, it is preferred that the vector be a so-called first-generation adenoviral vector. These adenoviral vectors are characterized by having a non-functional E1 gene region, and preferably a deleted
10 adenoviral E1 gene region. In some embodiments, the expression cassette is inserted in the position where the adenoviral E1 gene is normally located. In addition, these vectors optionally have a non-functional or deleted E3 region. The adenoviruses can be multiplied in known cell lines which express the viral E1 gene, such as 293 cells, or PerC.6 cells.

For convenience in manipulating the adenoviral vector, the adenovirus may be in a shuttle plasmid form. This invention is also directed to a shuttle plasmid vector which comprises a plasmid portion and an adenovirus portion, the adenovirus portion comprising an adenoviral genome which has a deleted E1 and optional E3
15 deletion, and has an inserted expression cassette comprising at least one codon-optimized HPV gene. In preferred embodiments, there is a restriction site flanking the adenoviral portion of the plasmid so that the adenoviral vector can easily be removed. The shuttle plasmid may be replicated in prokaryotic cells or eukaryotic cells.

Standard techniques of molecular biology for preparing and purifying
25 DNA constructs enable the preparation of the adenoviruses, shuttle plasmids and DNA immunogens of this invention.

If the vector chosen is plasmid DNA, it is preferred that the vector contain one or more promoters recognized by mammalian or insect cells. In a preferred embodiment, the plasmid would contain a strong promoter such as, but not
30 limited to the CMV promoter. The gene to be expressed would be linked to such a promoter. An example of such a plasmid would be the mammalian expression plasmid V1Jns as described (J. Shiver et. al. 1996, in *DNA Vaccines*, eds., M. Liu, et al. N.Y. Acad. Sci., N.Y., 772:198-208 and is herein incorporated by reference).

In some embodiment of this invention, the both the vaccine plasmid and the adenoviral vectors may be administered to a vertebrate in order to induce an immune response. In this case, the two vectors are administered in a "prime and boost" regimen. For example the first type of vector is administered, then after a
5 predetermined amount of time, for example, 1 month, 2 months, six months, or other appropriate interval, a second type of vector is administered. Preferably the vectors carry expression cassettes encoding the same polynucleotide or combination of polynucleotides.

Thus, another aspect of this invention is a method for inducing an
10 immune response against human papillomavirus in a vertebrate, comprising

- A) introducing into the vertebrate a first vector comprising a polynucleotide encoding an HPV protein selected from the group consisting of L1, E1, E2, and E7 proteins, wherein the polynucleotide is codon-optimized for expression in a human host cell;
- 15 B) allowing a predetermined amount of time to pass; and
- C) introducing into the vertebrate a second vector comprising adenoviral vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprises

- 20 i) a polynucleotide encoding an HPV protein selected from the group consisting of L1, E1, E2, and E7 proteins or mutant forms thereof, wherein the polynucleotide is codon-optimized for expression in a human host cell; and
- ii) a promoter operably linked to the polynucleotide.

25 In general, is preferred that the first vector be a plasmid vaccine vector and the second vector be an adenoviral vector. Thus this invention is directed to a method for inducing immune responses in a vertebrate comprising:

- A) introducing into the vertebrate a plasmid vaccine, wherein the plasmid vaccine comprises a plasmid portion and an expression cassette portion, the
30 expression cassette portion comprising:
 - i) a polynucleotide encoding an HPV protein selected from the group consisting of L1, E1, E2, and E7 proteins, wherein the polynucleotide is codon-optimized for expression in a human host cell; and
 - ii) a promoter operably linked to the polynucleotide;

B) allowing a predetermined amount of time to pass; and

C) introducing into the vertebrate an adenoviral vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising:

5 i) a polynucleotide encoding an HPV protein selected from the group consisting of L1, E1, E2, and E7 proteins or mutant forms thereof, wherein the polynucleotide is codon-optimized for expression in a human host cell; and

ii) a promoter operably linked to the polynucleotide.

In yet another embodiment of the invention, the codon-optimized
10 genes may be introduced into a recipient by way of a plasmid or adenoviral vector, as a "prime", and then a "boost" is accomplished by introducing into the recipient a polypeptide or protein which is essentially the same as that which is encoded by the codon-optimized gene. Fragments of a full length protein may be substituted, especially those which are immunogenic and/or include an epitope.

15 The amount of expressible DNA or transcribed RNA to be introduced into a vaccine recipient will depend partially on the strength of the transcriptional and translational promoters used and on the immunogenicity of the expressed gene product. In general, an immunologically or prophylactically effective dose of about 1 ng to 100 mg, and preferably about 10 μ g to 300 μ g of a plasmid vaccine vector is
20 administered directly into muscle tissue. An effective dose for recombinant adenovirus is approximately 10^6 - 10^{12} particles and preferably about 10^7 - 10^{11} particles. Subcutaneous injection, intradermal introduction, impression through the skin, and other modes of administration such as intraperitoneal, intravenous, or inhalation delivery are also contemplated. It is also contemplated that booster
25 vaccinations may be provided. Parenteral administration, such as intravenous, intramuscular, subcutaneous or other means of administration with adjuvants such as interleukin-12 protein, concurrently with or subsequent to parenteral introduction of the vaccine of this invention is also advantageous.

The vaccine vectors of this invention may be naked, that is,
30 unassociated with any proteins, adjuvants or other agents which impact on the recipients' immune system. In this case, it is desirable for the vaccine vectors to be in a physiologically acceptable solution, such as, but not limited to, sterile saline or sterile buffered saline or the DNA may be associated with an adjuvant known in the art to boost immune responses, such as a protein or other carrier. Agents which assist

in the cellular uptake of DNA, such as, but not limited to, calcium ions, may also be used to advantage. These agents are generally referred to herein as transfection facilitating reagents and pharmaceutically acceptable carriers. Techniques for coating microprojectiles coated with polynucleotide are known in the art and are also useful in connection with this invention.

The following examples are offered by way of illustration and are not intended to limit the invention in any manner.

EXAMPLES

10

EXAMPLE 1

Synthetic Gene Construction

Synthetic gene sequences for human papillomavirus proteins L1, E1, E2, and E7 were generated by reverse translation of amino acid sequences using the most frequently used codons found in highly expressed mammalian genes. (R. Lathe, 1985, *J. Mol. Biol.* 183:1-12, which is hereby incorporated by reference). Some adjustments to these codon-optimized sequences were made to introduce or remove restriction sites. Oligonucleotides based on these sequences were chemically synthesized (Midland Certified Reagents; Midland, TX) and assembled by PCR amplification. (J. Haas et. al., 1996, *Current Biology* 6:315-324; and *PCR Protocols*, M. Innis, et al, eds., Academic Press, 1990, both of which are hereby incorporated by reference).

Full-length sequences were cloned into the mammalian expression vector V1Jns (J. Shiver et. al. 1996, in *DNA Vaccines*, eds., M. Liu, et al. N.Y. Acad. Sci., N.Y., 772:198-208, which is hereby incorporated by reference) and sequenced by standard methodology. In cases where the actual sequence differed from the expected and resulted in amino acid substitution, that sequence was corrected by PCR mutagenesis as previously described (*PCR Protocols*, M. Innis, et al, eds., Academic Press, 1990, pg 177-180).

Protein expression was evaluated by transient transfection of equal quantities of plasmid DNA into 293 (transformed embryonic human kidney) cells which were harvested at 48 hr post DNA addition. Cell lysates were normalized to provide equal protein loadings. Analysis was by indirect immunofluorescence or

immunoblot (Western) analysis using sera prepared to each of the HPV proteins. (Current Protocols in Molecular Biology, eds., F. Ausabel, *et. Al.*, John Wiley and Sons, 1998, which is hereby incorporated by reference).

5

EXAMPLE 2

Synthesis of HPV 16 L1

The gene encoding HPV16 L1 was prepared by the annealing and extension of the 14 oligomers listed in FIGURE 17. Five separate extension reactions
10 were performed to create fragments of the gene, designated L1A, L1B, L1C, L1D and L1E by PCR using conditions similar to those described in EXAMPLE 3 and 4, below.

L1A was constructed using oligomer sequences MN4A1 (SEQ.ID.NO:9), MN4A2 (SEQ.ID.NO:16) and MN4A3 (SEQ.ID.NO:10) which were
15 amplified using the oligomers MN604 (SEQ.ID.NO:32) and MN596 (SEQ.ID.NO:24).

L1B was constructed using oligomer sequences MN4A4 (SEQ.ID.NO:17), MN4A5 (SEQ.ID.NO:11) and MN4A6 (SEQ.ID.NO:18) and were
20 amplified using the oligomers MN595 (SEQ.ID.NO:23) and MN598 (SEQ.ID.NO:26).

L1C was created using oligomer sequences MN4A7 (SEQ.ID.NO:12) and MN4A8 (SEQ.ID.NO:19) and were amplified using the oligomers MN597 (SEQ.ID.NO:25) and MN602 (SEQ.ID.NO:30).

L1D was created using oligomer sequences MN4A9 (SEQ.ID.NO:13),
25 MN4A10 (SEQ.ID.NO:20) and MN4A11 (SEQ.ID.NO:14) which were amplified using the oligomers MN597 (SEQ.ID.NO:25) and MN602 (SEQ.ID.NO:30).

L1E was created using oligomer sequences MN4A12 (SEQ.ID.NO:21), MN4A13 (SEQ.ID.NO:15) and MN4A14 (SEQ.ID.NO:22) which
30 were amplified using the oligomers MN601 (SEQ.ID.NO:29) and MN603 (SEQ.ID.NO:31).

Fragments L1A, L1B, L1C, L1D and L1E resulting from the PCR reactions were gel separated on low melting point agarose with the appropriately-sized products excised and purified using the AgaraseTM method (Boehringer Mannheim Biochemicals) as recommended by the manufacturer. Fragments L1A,

L1B and L1C were combined in a subsequent PCR reaction using oligomers MN604 (SEQ.ID.NO:32) and MN600 (SEQ.ID.NO:28) to assemble L1A-B-C; fragments L1D and L1E were assembled to L1D-E by subsequent PCR with the oligomers MN599 (SEQ.ID.NO:27) and MN603 (SEQ.ID.NO:31). The complete gene was then assembled by additional PCR reactions in which fragments L1A-B-C, L1D-E were combined with oligomers MN604 (SEQ.ID.NO:32) and MN603 (SEQ.ID.NO:31) in a final series of PCR reactions. The resulting 1.5 kb product was gel isolated, digested with Bgl II and subcloned into the V1Jns and sequenced. In instances where a mutation was observed, it was corrected by PCR mutagenesis as described in

EXAMPLE 1. DNA was isolated from a clone with the correct HPV16 L1 DNA sequence and proper orientation within V1Jns for use in transient transfection assays as described in EXAMPLE 1.

Transfection Results (HPV16 L1)

FIGURE 9 shows the HPV16 L1 immunoblot results of lysates of 293 cells transiently-transfected with the V1Jns plasmid containing either the native or the codon-optimized, synthetic HPV16 L1. Lanes a, b and c are the expression levels achieved using the synthetic HPV16 L1 expression construct. High levels of immunoreactive material are apparent in each of these lanes with the predominant band at approximately 55 kDa, consistent with the expected molecular weight for full-length HPV16 L1. In contrast, virtually no immunoreactive material is apparent in the lanes containing lysates transfected with the native HPV16 L1/ V1Jns plasmid (lanes d, e, and f). Since all cell lysate loadings were normalized and equivalent DNA amounts were used in the transfections, these findings indicate that the synthetic gene sequence greatly increased the levels of HPV16 L1 protein accumulation relative to that of the native gene sequence.

EXAMPLE 3

Synthesis of HPV 16 E1

The gene encoding the modified form of HPV16 E1 was assembled from a series of fragments: E1A, E1B, E1C, E1D, E1E and E1F, using the oligomers listed in FIGURE 18. E1A was formed by assembly of oligomers MN605

(SEQ.ID.NO:33), MN606 (SEQ.ID.NO:34) and MN607 (SEQ.ID.NO:35) and amplified using oligomers MN636 (SEQ.ID.NO:64) and MN624 (SEQ.ID.NO:52).

5 E1B was formed by assembly of oligomers MN608 (SEQ.ID.NO:36), MN609 (SEQ.ID.NO:37) and MN610 (SEQ.ID.NO:38) which were amplified with oligomers MN623 (SEQ.ID.NO:51) and MN626 (SEQ.ID.NO:54).

E1C was formed by assembly of oligomers MN611 (SEQ.ID.NO:39) and MN612 (SEQ.ID.NO:40) which were amplified with oligomers MN625 (SEQ.ID.NO:53) and MN628 (SEQ.ID.NO:56).

10 E1D was formed by assembly of oligomers MN613 (SEQ.ID.NO:41), MN614 (SEQ.ID.NO:42) and MN615 (SEQ.ID.NO:43) which were amplified with oligomers MN627 (SEQ.ID.NO:55) and MN630 (SEQ.ID.NO:58).

E1E was formed by assembly of oligomers MN616 (SEQ.ID.NO:44), MN617 (SEQ.ID.NO:45) and MN618 (SEQ.ID.NO:46) which were amplified with oligomers MN629 (SEQ.ID.NO:57) and MN632 (SEQ.ID.NO:60).

15 E1F was formed by assembly of oligomers MN619 (SEQ.ID.NO:47), MN620 (SEQ.ID.NO:48) and MN621 (SEQ.ID.NO:49) which were amplified with oligomers MN631 (SEQ.ID.NO:59) and MN635 (SEQ.ID.NO:63).

20 Products of these PCR reactions were gel isolated and combined in subsequent rounds of PCR to form a 2 kb gene fragment encoding HPV16 E1 using methods described above. The resulting HPV16 E1 was inserted into the V1Jns expression vector as above and utilized in transient transfection studies as described in EXAMPLE 1.

Transfection Results (HPV16 E1)

25 FIGURE 10 shows the HPV16 E1 immunoblot results of lysates of 293 cells transiently-transfected with the V1Jns plasmid containing either the native, or the codon-optimized, synthetic HPV16 E1. Lanes b and e are the expression levels achieved using the codon-optimized HPV16 E1 expression construct. High levels of HPV16 E1-specific immunostaining are apparent with a predominant band in lanes b and e at 72 kDa, consistent with the expected size for full-length HPV16 E1. In
30 addition, there a number of smaller immunoreactive products which appear to be E1-specific as they are not observed in the mock transfected control (lane c).

A very different expression profile is observed in lysates of cells transfected with the native HPV16 E1/V1Jns construct, however. As shown in lanes a and d, only minimal amounts of immunoreactive material can be visualized which is not present in the mock transfection control. Since all cell lysate loadings were normalized and equivalent DNA amounts were used in the transfections these findings indicate that the synthetic gene sequence greatly increased the levels of HPV16 E1 protein accumulation relative to that of the native gene sequence.

EXAMPLE 4

Synthesis of HPV 16 E2

Fragment AD. A 50 μ l reaction containing oligonucleotides 13856-307-2A (SEQ.ID.NO:65), 13856-307-2B (SEQ.ID.NO:71), 13856-307-2C (SEQ.ID.NO:66), and 13856-307-2D (SEQ.ID.NO:72), at 150 nM each, dNTPs 0.5 mM each, Native buffer (Stratagene; La Jolla, CA) and 1 μ L Native Pfu DNA polymerase (Stratagene) was incubated in a GeneAmp 9700 thermocycler (Perkin Elmer Applied Biosystems; Foster City, CA) under the following conditions: 95°C, 2 min.; 20 cycles of 95°C, 45 sec.; 55°C, 45 sec.; and 72°C, 2.5 min. Added to the reaction were primers 13856-307-2PA (SEQ.ID.NO:78) and 13856-307-2PD (SEQ.ID.NO:82) to a final concentration of 400 nM each, and 1 μ L of Native Pfu DNA polymerase. The mixture was incubated for 2 min at 95°C and then 25 cycles of 95°C, 45 sec; 55°C, 45 sec; and 72°C, 2.5 min. The gel-isolated full-length fragment AD was amplified for 20 cycles under the same conditions using primers 13856-307-2PA (SEQ.ID.NO:78) and 13856-307-2PD (SEQ.ID.NO:82).

Fragment EH. A 50 μ l reaction containing oligonucleotides 13856-307-2E (SEQ.ID.NO:67), 13856-307-2F (SEQ.ID.NO:73), 13856-307-2G (SEQ.ID.NO:68), and 13856-307-2H (SEQ.ID.NO:74) at 150 nM each, dNTPs 0.5 mM each, Native buffer and 1 μ L Native Pfu DNA polymerase was incubated under the following conditions: 95°C, 2 min; 20 cycles of 95°C, 2 min.; 45 sec.; 55°C, 45 sec.; and 72°C, 2.5 min. Added to the reaction were primers 13856-307-2PE (SEQ.ID.NO:80) and 13856-307-2PH (SEQ.ID. NO:83) to a final concentration of 400 nM each, and 1 μ L of Native Pfu DNA polymerase. The mixture was incubated for 95°C, 2 min.; then 25 cycles of 95°C, 45 sec.; 55°C, 45 sec.; and 72°C, 2.5 min.

- Fragment IL. A 50 μ l reaction containing oligonucleotides 13856-307-2I (SEQ.ID.NO:69), 13856-307-2J (SEQ.ID.NO:75), 13856-307-2K (SEQ.ID.NO:70), and 13856-307-2L (SEQ.ID.NO:76) at 150 nM each, dNTPs 0.5 mM each, Native buffer and 1 μ L Native Pfu DNA polymerase was incubated under the following conditions: 95°C, 2 min; 20 cycles of 95°C, 2 min.; 45 sec.; 55°C, 45 sec.; and 72°C, 2.5 min. Added to the reaction were primers 13856-307-2PI (SEQ.ID.NO:81) and 13856-307-2PL (SEQ.ID.NO. 84) to a final concentration of 400 nM each, and 1 μ L of Native Pfu DNA polymerase. The mixture was incubated at 95°C, 2 min.; then 25 cycles of 95°C, 45 sec.; 55°C, 45 sec.; and 72°C, 2.5 min.
- 10 Fragment AH. A 50 μ l reaction containing 1.5 μ l each of AD and EH PCR products, dNTPs 0.5 mM each, Native buffer and 1 μ L Native Pfu DNA polymerase was incubated under the following conditions: 95°C, 2 min; 20 cycles of 95°C, 45 sec.; 55°C, 45 sec.; and 72°C, 3.5 min. Added to the reaction were primers 13856-307-2PA (SEQ.ID.NO:78) and 13856-307-2PH (SEQ.ID.NO:83) to a final
- 15 concentration of 400 nM each, and 1 μ L of Native Pfu DNA polymerase. The mixture was incubated at 95°C, 2 min.; then 25 cycles of 95°C, 45 sec.; 55°C, 45 sec.; and 72°C, 3.5 min.
- Fragment IM. A 50 μ l reaction containing 1 μ l of IL PCR product, oligonucleotides 13856-307-2M (SEQ.ID.NO:77) and 13856-307-2PI (SEQ.ID.NO:81) each at a final concentration of 400 nM, dNTPs 0.5 mM each, Native buffer and 1 μ L Native Pfu DNA polymerase was incubated under the following conditions: 95°C, 2 min; 25 cycles of 95°C, 45 sec.; 55°C, 45 sec.; and 72°C, 4 min.
- 20
- Assembly of AM, full-length HPV16 E2. A 50 μ l reaction containing 1.5 μ l each of fragments AH and IM, dNTPs 0.5 mM each, Native buffer and 1 μ L Native Pfu DNA polymerase was incubated under the following conditions: 95°C, 2 min; 20 cycles of 95°C, 45 sec.; 55°C, 45 sec.; and 72°C, 4 min. Added to the reaction were primers 13856-307-2PA (SEQ.ID.NO:78) and 13856-307-2PM (SEQ.ID.NO:79) at a final concentration of 400 μ M each, and 1 μ L of Native Pfu
- 25
- 30 DNA polymerase. The mixture was incubated at 95°C, 2 min.; then 25 cycles of 95°C, 45 sec.; 55°C, 45 sec.; and 72°C, 4 min. The resultant full-length fragment was isolated by electrophoresis through a 1.2% agarose gel the DNA recovered with a QIAquick column (Qiagen; Santa Clarita, CA) and subcloned into the expression vector V1Jns for evaluation.

Transfection Results (HPV16 E2)

FIGURE 11 shows the HPV16 E2 immunoblot results of lysates of 293 cells transiently-transfected with the V1Jns plasmid containing either the native, or the synthetic HPV16 E2. Lanes c and d are the expression levels achieved using the codon-optimized HPV16 E2 expression construct. High levels of HPV16 E2-specific immunostaining are visible which appear to be E2-specific as they are not observed in the mock transfected control (lane c).

A very different expression profile is observed in lysates of cells transfected with the native HPV16 E2/V1Jns construct, however. As shown in lane e, no immunoreactive material can be visualized. Since all cell lysate loadings were normalized and equivalent DNA amounts were used in the transfections, these findings indicate that the synthetic gene sequence greatly increased the levels of HPV16 E2 protein accumulation relative to those of the native gene sequence.

EXAMPLE 5

Synthesis of HPV 16 E7

The gene encoding HPV16 E7 was assembled from a series of fragments, made using oligomers listed in FIGURE 20.

A 50 μ l reaction containing oligonucleotides 13856-307-7A (SEQ.ID.NO:85), 13856-307-7B (SEQ.ID.NO:87), 13856-307-7C (SEQ.ID.NO:86), and 13856-307-7D (SEQ.ID.NO:88) at 150 nM each, dNTPs 0.5 mM each, Native buffer (Stratagene; La Jolla, CA) and 1 μ L Native Pfu DNA polymerase (Stratagene) was incubated in a GeneAmp 9700 thermocycler (Perkin Elmer Applied Biosystems; Foster City, CA) under the following conditions: 95°C, 2 min; 20 cycles of 95°C, 45 sec.; 55°C, 45 sec. and 72°C, 2.5 min. Added to the reaction were primers 13856-307-7PA (SEQ.ID.NO:89) and 13856-307-7PD (SEQ.ID.NO:90) to a final concentration of 400 nM, and 1 μ L of Native Pfu DNA polymerase. The mixture was incubated for 25 cycles of 95°C, 45 sec.; 55°C, 45 sec. and 72°C, 2.5 min.

The resultant full-length fragment was isolated by electrophoresis through a 1.2% agarose gel in TBE (Current Protocols in Molecular Biology, eds., F. Ausabel, *et. al.*, John Wiley and Sons, 1998, which is hereby incorporated by reference), stained with ethidium bromide, cut from the gel and recovered through a

GenElute column (Supleco; Bellefonte, PA) and resuspended in 20 μ l water. The sequence was further amplified in a 51 μ l reaction containing 2 μ l of fragment, 0.5 μ M each of oligonucleotides 13856-307-7PA (SEQ.ID.NO:89) and 13856-307-7PD, (SEQ.ID.NO:90) dNTPs 0.5mM each, Native buffer and Native Pfu DNA polymerase. The reaction was subjected to 20 cycles of 95°C, 45 sec.; 55°C, 45 sec. and 72°C, 2.5 min. The final amplified product isolated by electrophoresis as described above; the DNA recovered with a QIAquick column (Qiagen; Santa Clarita, CA) and subcloned into V1Jns.

10 Transfection Results (HPV16 E7)

FIGURE 12 shows the HPV16 E7 immunoblot results of lysates of 293 cells transiently-transfected with the V1Jns plasmid containing either the native (lane e) or synthetic HPV16 E7 (lanes c and d). High levels of HPV16 E7-specific immunostaining are visible in the synthetic HPV16 E7 gene cell lysate lanes which are considerably more intense in appearance than that of the native HPV16 E7 gene cell lysate (lane e). Lanes a and b are negative transfection controls which show the antibody staining is specific to HPV16 E7 sequences. Since all cell lysate loadings were normalized and equivalent DNA amounts were used in the transfections, these findings indicate that the synthetic gene sequence greatly increased the levels of HPV16 E2 protein accumulation relative to those of the native gene sequence.

EXAMPLE 6

Synthesis of the E7 and E2 -encoding genes from HPV6a and HPV18:

25 The genes encoding HPV6a E7 and HPV 18 E7 were constructed using similar methods as described in EXAMPLE 4, except that the oligomers used to create the HPV6a E7 and HPV 18 E7 genes contain the sequences listed in FIGURE 21 and FIGURE 22, respectively. The construction of the synthetic genes encoding HPV6a E2 and HPV18 E2 was performed in a similar manner as detailed in
30 EXAMPLE 5 using the oligomer sequences listed in FIGURE 23 and FIGURE 24 respectively.

Transfection Results: HPV6a E7 and HPV 18 E7

FIGURE 13 shows the HPV6a E7 immunoblot results of lysates of 293 cells transiently-transfected with the V1Jns plasmid containing synthetic HPV6a E7 (lanes b and c). High levels of HPV6a E7-specific immunostaining are visible in the region expected for full-length HPV6a E7. A similar profile is found in FIGURE 14 by HPV18 E7 immunoblot analysis of lysates of 293 cells transiently-transfected with the V1Jns plasmid containing synthetic HPV6a E7 (lanes b, c, d and e). High levels of HPV18 E7-specific immunostaining are visible where full-length HPV18 E7 would be found as indicated by the location of the purified HPV18 protein control (lane f). There does not appear to be any stained material in the negative control lane a which indicates the staining in the other lanes is HPV18 E7-specific.

Expression of the synthetic gene encoding HPV6a E2 in V1Jns was evaluated by immunoblot analysis of transfected 293 cells which is shown in FIGURE 15. Lanes a and b are cell lysates of the synthetic HPV6a E2 transfectants; lanes c and d are negative controls. The analogous experiment is shown for HPV18 E2 expression in FIGURE 16. Lanes c and d are the cell lysates of transfections receiving the synthetic HPV18 E2 gene; lanes a and b are the negative controls. Both of these figures show measurable levels of E2 product accumulation when the codon-optimized, synthetic gene is expressed in mammalian cells.

These results indicate that the synthetic gene rebuilding is not limited to HPV16 genes. Rather, codon optimization of other HPV types also permits significant levels of E7 and E2 product accumulation in mammalian cells.

EXAMPLE 7

Construction of replication-defective FG-Ad expressing HPV antigen

Starting vectors

Shuttle vector pHCMVIBGHpA1 contains Ad5 sequences from bp1 to bp 341 and bp 3534 to bp 5798 with a expression cassette containing human cytomegalovirus (HCMV) promoter plus intron A and bovine growth hormone polyadenylation signal.

The adenoviral backbone vector pAdE1-E3- (also named as pHVad1) contains all Ad5 sequences except those nucleotides encompassing the E1 and E3 region.

Construction of Ad5. HPV16 E2

1. Construction of adenoviral shuttle plasmid pA1-CMVI-HPV16 E2 containing HPV16 E2 under the control of human CMV promoter and intron A.

5 The HPV16 E2 insert was excised from pV1JNS-HPV16 E2 by restriction enzyme Bgl II, EcoRI and then cloned into Bgl II, EcoRI digested shuttle vector pHCMVIBGHpA1.

2. Homologous recombination to generate plasmid form of recombinant adenoviral vector pAd-CMVI-HPV16 E2 containing HPV16 E2 expression cassette.

10 Shuttle plasmid pA1-CMVI- HPV16 E2 was digested with restriction enzymes BstZ17 and SgrA1 and then co-transformed into *E. coli* strain BJ5183 with linearized (ClaI digested) adenoviral backbone plasmid pAdE1-E3-. A colony was verified by PCR analysis. The vector was transformed to competent *E. coli* HB101
15 for large quantity production of the plasmid.

3. Generation of recombinant adenovirus Ad.CMVI- HPV16 E2 in 293 cells.

 The pAd plasmid was linearized by restriction enzyme PacI and transfected to 293 cells using CaPO₄ method (Invitrogen kit). Ten days later, 10
20 plaques were picked and grown in 293 cells in 35-mm plates. PCR analysis of the adenoviral DNA showed virus were positive for HPV16 E2.

4. Evaluation of large scale recombinant adenovirus Ad.CMVI- HPV16 E2

 A selected clone was grown into large quantities through multiple
25 rounds of amplification in 293 cells. Expression of HPV16 E2 was also verified by ELISA and Western blot analysis of the 293 or COS cells infected with the recombinant adenovirus. The recombinant adenovirus was used for evaluation in mice and rhesus monkeys.

30 Method of Treatment

 A person in need of therapeutic or prophylactic immunization against infection with human papillomavirus virus is injected with HPV DNA encoding all or part of; HPV L1, E1, E2, E4 or E7 and combinations thereof. The injection may be i.p., subcutaneous, intramuscular or intradermal. The HPV DNA may be used as a

primer of the immune response or may be used as a booster of the immune response. The injection of DNA may antedate, coincide or follow injection of the person with a pharmaceutical composition comprising HPV virus like particles (containing only L1 protein or containing both L1 and L2 proteins, or containing mutant forms of one or more proteins), capsomeres, inactivated HPV, attenuated HPV, compositions comprising HPV-derived proteins, or combinations thereof.

EXAMPLE 8

The use of a synthetically-expressed HPV E protein as a model tumor antigen.

10

Generation of a tumor cell line that expresses HPV 16 E2.

A Not I-Hind III restriction digest fragment containing the synthetic coding sequence for HPV 16 E2 (see above) was ligated with Not I, Hind III digested expression vector pBJ/neo/CCR2B which has a neomycin resistance marker and drives the expression of the transgene with the HCMV immediate early promoter. The resultant plasmid, pBJ-16 E2, was characterized by restriction digestion, sequence analysis of the cloning junctions, and the ability to induce E2 protein expression in transiently-transfected A293 or CT26 cells. A stable cell line was generated transfection of CT26 cells using Lipofectamine (Gibco BRL). CT26 cells, a fully-transformed line derived from a BALB/c mouse colon carcinoma, have been widely used to present model tumor antigens. (Brattain et al., 1980 *Cancer Research* 40:2142-2146; Fearon, E. et al., 1988 *Cancer Research*, 48:2975-2980; both of which are incorporated by reference).

After 48 hours, cells were trypsinized, diluted 1:10, 1:100, 1:1000 or 1:10000 into medium and plated in 100mm² plates. After 24 hours, the medium was replaced with selection medium containing 400µg/mL G418. After two to three weeks, well-isolated colonies of cells were recovered using cloning rings and transferred to 48-well plates. One clone was positive for E2 expression by immunoblot analysis and was subjected to two further rounds of cloning by limiting dilution. One G418 resistant, E2-positive clonal isolate was used to established the cell line JCL-031. (FIGURE 25).

When inoculated into (syngeneic) BALB/c mice by subcutaneous injection, JCL-031 cell induced tumors with the kinetics similar to those as the parental CT26 line. Cells cultured from recovered tumors were G418 resistant and expressed E2.

5

Induction of immunity in mice by immunization with V1Jns:E2 DNA.

BALB/c mice were immunized multiple times by intramuscular injection with the DNA V1Jns:16E2. Splens from two randomly-chosen mice in each dose group were pooled, splenocytes prepared, and assayed in a murine
 10 interferon gamma Elispot assay. (Lalvani et al. 1997 *J. Exp. Med.* 186: 859-865; Forsthuber, T., et al 1996 *Science* 271: 1728-1730;. Chu, R. et al. 1997. *J. Exp. Med.* 186: 1623-1631, each of which is incorporated by reference.) Splenocyte cultures were incubated at 37°C for 24 hr. in the presence of a pool of 36 overlapping 20 amino acid residue peptides (final concentration, 4µg/mL each) scanning the full
 15 length of HPV 16 E2. Interferon gamma was captured on the substrate by monoclonal antibody (mAb) R4-6A2 (Pharmagin), and detected with biotinylated mAb XMG1.2 (Pharmagin) and a strepavidin-alkaline phosphatase conjugate (Pharmagin). Results are shown in Table A, below. The immunized mice developed CD4⁺ immune responses to HPV (Table A, below).

20

Immunization with E2 DNA did not induce detectable anti-E2 antibody responses.

Table A

Dose Group	Immunization	E2-specific spots (per 10 ⁶ cells)
1	E2 DNA 1	392
2	E2 DNA 2	96
3	E2 DNA 3	134
4	Control DNA 1	0
5	Control DNA 2	2

Protection from challenge with JCL-031 cells.

BALB/c mice, immunized with V1Jns:E2 DNA, or control DNA, were challenged by subcutaneous injection of 5×10^5 JCL-031 cells into the left inguinal region. Tumor growth was monitored by palpation or caliper measurement for a four-week period. FIGURE 26 reports the fraction of each dose group that remained tumor free. The group that had been immunized with an E2-expressing plasmid was significantly protected from tumor development compared to the control group.

WHAT IS CLAIMED IS:

1. A synthetic polynucleotide comprising a sequence encoding a human papillomavirus (HPV) protein, or mutated form of a HPV protein which has reduced protein function as compared to wild-type protein, but which maintains immunogenicity, the polynucleotide sequence comprising codons optimized for expression in a human host.
2. A polynucleotide according to Claim 1 wherein the protein is selected from the group consisting of: L1, L2, E1, E2, E4, E5, E6 and E7.
3. A polynucleotide according to Claim 2 wherein the protein is selected from the group consisting of: L1, E1, E2, and E7.
4. A polynucleotide according to Claim 2 which is DNA.
5. A polynucleotide according to Claim 4 wherein the protein is L1 and is from an HPV selected from the group consisting of: HPV6a, HPV6b, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, and HPV68.
6. A polynucleotide according to Claim 5 wherein the protein is an HPV16 L1 protein.
7. A polynucleotide according to Claim 6 which comprises the polynucleotide of FIGURE 1 (SEQ.ID.NO: 1).
8. A polynucleotide according to Claim 4 wherein the protein is an E1 protein or a mutated E1 protein and is from an HPV selected from the group consisting of: HPV6a, HPV6b, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, and HPV 68.
9. A polynucleotide according to Claim 8 wherein the protein is a mutated form of E1.

10. A polynucleotide according to Claim 8 which is an HPV16 E1 protein.
- 5 11. A polynucleotide according to Claim 10 which comprises the polynucleotide of FIGURE 2 (SEQ. ID.NO:2).
- 10 12. A polynucleotide according to Claim 4 wherein the protein is E2 protein or a mutated E2 protein and is from an HPV selected from the group consisting of: HPV6a, HPV6b, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, and HPV 68.
- 15 13. A polynucleotide according to Claim 12 wherein the protein is a mutated E2 protein.
14. A polynucleotide according to Claim 11 which is an HPV16 E2 mutated protein.
- 20 15. A polynucleotide according to Claim 14 which comprises the polynucleotide of FIGURE 3 (SEQ. ID.NO: 3).
- 25 16. A polynucleotide according to Claim 4 wherein the protein is E7 or an E7 mutant and is from an HPV selected from the group consisting of: HPV6a, HPV6b, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV68.
17. A polynucleotide according to Claim 16 wherein the protein is an HPV6a protein.
- 30 18. A polynucleotide according to Claim 17 which comprises the polynucleotide of FIGURE 4 (SEQ. ID.NO:4).

19. An adenoviral vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising:

- 5 A) a polynucleotide encoding an HPV protein selected from the group consisting of L1, E1, E2, and E7 proteins or mutant forms thereof, wherein the polynucleotide is codon-optimized for expression in a human host cell; and
- B) a promoter operably linked to the polynucleotide.

20. A vector according to Claim 19 wherein the adenoviral genome
10 also contains a deleted E3 region.

21. A shuttle plasmid vector comprising a plasmid portion and an adenoviral portion, the adenoviral portion comprising: an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises
15 an expression cassette comprising:

- A) a polynucleotide encoding an HPV protein selected from the group consisting of L1, E1, E2, and E7 proteins, wherein the polynucleotide is codon-optimized for expression in a human host cell; and
- B) a promoter operably linked to the polynucleotide.

20

22. A vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising:

- A) a polynucleotide encoding an HPV protein selected from the group consisting of L1, E1, E2, and E7 proteins, wherein the polynucleotide is codon-
25 optimized for expression in a human host cell; and
- B) a promoter operably linked to the polynucleotide.

23. A plasmid according to Claim 22 wherein the plasmid portion
is V1Js.

30

24. A method for inducing immune responses in a vertebrate which comprises introducing between 1 ng and 100 mg of the polynucleotide of Claim 1 into the tissue of the vertebrate.

25. A method for inducing immune responses in a vertebrate which comprises introducing between 10^{11} - 10^{12} particles of an adenoviral vector carrying the polynucleotide of Claim 1 into the tissue of the vertebrate.

5 26. A method for inducing an immune response against human papillomavirus in a vertebrate, comprising

A) introducing into the vertebrate a first vector comprising a polynucleotide encoding an HPV protein selected from the group consisting of L1, E1, E2, and E7 proteins, wherein the polynucleotide is codon-optimized for
10 expression in a human host cell;

B) allowing a predetermined amount of time to pass; and

C) introducing into the vertebrate a second vector comprising adenoviral vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression
15 cassette comprises

i) a polynucleotide encoding an HPV protein selected from the group consisting of L1, E1, E2, and E7 proteins or mutant forms thereof, wherein the polynucleotide is codon-optimized for expression in a human host cell; and

ii) a promoter operably linked to the polynucleotide.

20 27. A method according to Claim 26 wherein the vertebrate is human.

25 28. A method for inducing immune responses in a vertebrate comprising

A) introducing into the vertebrate a plasmid vaccine, wherein the plasmid vaccine comprises a plasmid portion and an expression cassette portion, the expression cassette portion comprising:

i) a polynucleotide encoding an HPV protein selected from the
30 group consisting of L1, E1, E2, and E7 proteins, wherein the polynucleotide is codon-optimized for expression in a human host cell; and

ii) a promoter operably linked to the polynucleotide;

B) allowing a predetermined amount of time to pass; and

C) introducing into the vertebrate an adenoviral vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising:

- 5 i) a polynucleotide encoding an HPV protein selected from the group consisting of L1, E1, E2, and E7 proteins or mutant forms thereof, wherein the polynucleotide is codon-optimized for expression in a human host cell; and
- ii) a promoter operably linked to the polynucleotide.

10 29. A method according to Claim 28 wherein the vertebrate is human.

30. A method of making a HPV protein comprising expressing in a host cell a synthetic polynucleotide encoding a human papillomavirus (HPV) protein, or mutated form of a HPV protein which has reduced protein function as compared to

15 wild-type protein, but which maintains immunogenicity, polynucleotide sequence comprising codons optimized for expression in a human host.

1/31

FIGURE 1

SEQ.ID.NO:1 Sequence of the Codon-Optimized HPV16 L1

ATGAGCCTGTGGCTGCCCAGCGAGGCCACCGTGTACCTGCCTCCCGTGCCC
GTGAGCAAGGTGGTGAGCACCGACGAGTACGTGGCCCGCACCAACATCTA
CTACCACGCCGGCACCAGCCGCCTGCTGGCCGTGGGCCACCCCTACTTCCC
CATCAAGAAGCCCAACAACAACAAGATCCTGGTGCCCAAGGTGAGCGGCC
TGCAGTACCGCGTGTTCGCGATCCACCTGCCCCGACCCCAACAAGTTCGGCT
TCCCCGACACAAGCTTCTACAACCCCGACACCCAGCGCCTGGTGTGGGCCT
GCGTGGGCGTGGAGGTGGGCGCGGCCAGCCCCTGGGCGTGGGCATCAGC
GGCCACCCCTGCTGAACAAGCTGGACGACACCGAGAACGCCAGCGCCTA
CGCCGCCAACGCCGGCGTGGACAACCGCGAGTGCATCAGCATGGACTACA
AGCAGACCCAGCTGTGCCTGATCGGCTGCAAGCCTCCCATCGGCGAGCACT
GGGGCAAGGGCAGCCCCTGCACCAACGTGGCCGTGAACCCCGGCGACTGC
CCTCCCCTGGAGCTGATCAACACCGTGATCCAGGACGGCGACATGGTGGA
CACCGGCTTCGGCGCCATGGACTTCACCACCCTGCAGGCCAACAAGAGCG
AGGTGCCCCTGGACATCTGCACCAGCATCTGCAAGTACCCCGACTACATCA
AGATGGTGAGCGAGCCCTACGGCGACAGCCTGTTCTTCTACCTGCGCCGCG
AGCAGATGTTTCGTGCGCCACCTGTTCAACCGCGCCGGCGCCGTGGGCGAG
AACGTGCCCCGACGACCTGTACATCAAGGGCAGCGGCAGCACCGCCAACCT
GGCCAGCAGCAACTACTTCCCCACTCCAGCGGCAGCATGGTGACCAGCG
ACGCCCAAATCTTCAACAAGCCCTACTGGCTGCAGCGCGCCCAGGGCCACA
ACAACGGCATCTGCTGGGGCAACCAGCTGTTTCGTGACCGTGGTGGACACC
ACCCGCAGCACCAACATGAGCCTGTGCGCCGCCATCAGCACCGAGCGAGAC
CACCTACAAGAACCAACTTCAAGGAGTACCTGCGCCACGGCGAGGAGT
ACGACCTGCAGTTCATCTTCCAGCTGTGCAAGATCACCTGACCGCCGACG
TGATGACCTACATCCACAGCATGAACAGCACCATCCTGGAGGACTGGAAC
TTCGGCCTGCAGCCCCCTCCCGGCGGTACCCTGGAGGACACCTACCGCTTC
GTGACCAGCCAGGCCATCGCCTGCCAGAAGCACACCCCTCCCGCTCCCAAG
GAGGATCCCCTGAAGAAGTACACCTTCTGGGAGGTGAACCTGAAGGAGAA
GTTACGCGCCGACCTGGACCAGTTCGCCCTGGGCGCAAGTTCCTGCTGCA
GGCCGGCCTGAAGGCCAAGCCCAAGTTCACCCTGGGCAAGCGCAAGGCCA
CCCCACCAACAGCAGCACCAAGCACCGCCAAGCGCAAGAAGCGCAAG
CTGTAA

2/31

FIGURE 2

SEQ.ID.NO:2 Codon-Optimized HPV16 E1-G482D.W439R Mutant:

ATGGCCGACCCCGCCGGCACCAACGGCGAGGAGGGCACCGGCTGCAACGG
CTGGTTCTACGTGGAGGCCGTGGTGGAGAAGAAGACCGGCGACGCCATCA
GCGACGACGAGAACGAGAACGACAGCGACACCGGCGAGGACCTGGTGG
CTTCATCGTGAACGACAACGACTACCTGACCCAGGCCGAGACCGAGACCG
CCCACGCCCTGTTCAACGCCAGGAGGCCAAGCAGCACCGCGACGCCGTGC
AGGTGCTGAAGCGCAAGTACCTGGGCAGCCCCCTGAGCGACATCAGCGGC
TGCCTCGACAACAACATCAGCCCCCGCCTGAAGGCCATCTGCATCGAGAA
GCAGAGCCGCGCCGCCAAGCGCCGCCTGTTTCGAGAGCGAGGACAGCGGCT
ACGGCAACACCGAGGTGGAGACCCAGCAGATGCTGCAGGTGGAGGGCCGC
CACGAGACCGAGACCCCTGCAGCCAGTACAGCGGCGGCAGCGGCGGCGG
CTGCAGCCAGTACAGCAGCGGCAGCGGCGGCGAGGGCGTGAGCGAGCGCC
ACACCATCTGCCAGACCCCTCTGACCAACATCCTGAACGTGCTGAAGACCA
GCAACGCCAAGGCCGCCATGCTGGCCAAGTTCAAGGAGCTGTACGGCGTG
AGCTTCAGCGAGCTGGTGCGCCCTTCAAGAGCAACAAGAGCACCTGCTG
CGACTGGTGTCATCGCCGCCTTCGGCCTGACCCCCAGCATCGCCGACAGCAT
CAAGACCCTGCTGCAGCAGTACTGCCTGTACCTGCACATCCAGAGCCTGGC
CTGCAGCTGGGGCATGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG
AGAACC CGCGAGACCATCGAGAAGCTGCTGAGCAAGCTGCTGTGCGTGAGC
CCCATGTGCATGATGATCGAGCCTCCCAAGCTTCGCAGCACCGCCGCCGCC
CTGTACTGGTACAAGACCGGCATCAGCAACATCAGCGAGGTGTACGGCGA
CACCCCCGAGTGGATCCAGCGCCAGACCGTGCTGCAGCACAGCTTCAACG
ACTGCACCTTCGAGCTGAGCCAGATGGTGCAGTGGGCCTACGACAACGAC
ATCGTGGACGACAGCGAGATCGCCTACAAGTACGCCAGCTGGCCGACAC
CAACAGCAACGCCAGCGCCTTCCTGAAGAGCAACAGCCAGGCCAAGATCG
TGAAGGACTGCGCCACCATGTGCCGCCACTACAAGCGCGCCGAGAAGAAG
CAGATGAGCATGAGCCAGTGGATCAAGTACCGCTGCGACCGCGTGACGA
CGGCGGCGACCGCAAGCAGATCGTGATGTTCTGCGCTACCAGGGCGTGG
AATTCATGAGCTTCCTGACCGCCCTGAAGCGCTTCCTGCAGGGCATCCCCA
AGAAGAACTGCATCCTGCTGTACGGCGCCGCCAACACCGACAAGAGCCTG
TTCGGCATGAGCCTGATGAAGTTCCTGCAGGGCAGCGTGATCTGCTTCGT
GAACAGCAAGAGCCACTTCTGGCTGCAGCCCCTGGCCGACGCCAAGATCG
GCATGCTGGACGACGCCACCGTGCCCTGCTGGAACCTACATCGACGACAAC
CTGCGCAACGCCCTGGACGGCAACCTGGTGAGCATGGACGTGAAGCACCG
CCCCCTGGTGCAGCTGAAGTGCCCTCCCCTGCTGATCACCAGCAACATCAA
CGCCGGCACCGACAGCCGCTGGCCCTACCTGCACAACCGCCTGGTGGTGT
CACCTTCCCCAACGAGTTCCCTTCGACGAGAACGGTAACCCCGTGTACGA
GCTGAACGACAAGAACTGGAAGAGCTTCTTCAGCCGCACCTGGAGCCGCC
TGAGCCTGCACGAGGACGAGGACAAGGAGAACGACGGCGACAGCCTGCCC
ACCTTCAAGTGCGTGAGCGGCCAGAACACCAACACCCCTGTAA

3/31

FIGURE 3

SEQ.ID.NO.:3 Sequence of the Codon-Optimized HPV16E2-E39A.I73A Mutant:

ATGGAGACCCTGTGCCAGCGCCTGAACGTGTGCCAGGACAAGATCCTGAC
CCTACTACGAGAACGACAGCACCGACCTGCGCGACCACATCGACTACTGGA
AGCACATGCGCCTGGCCTGCGCCATCTACTACAAGGCCCGCGAGATGGGC
TTCAAGCACATCAACCACCAGGTGGTGCCACCCTGGCCGTGAGCAAGAA
CAAGGCCCTGCAGGCCGCGGAGCTGCAGCTGACCCTGGAGACCATCTACA
ACAGCCAGTACAGCAACGAGAAAGTGGACCCTGCAGGACGTGAGCCTGGAG
GTGTACCTGACCGCCCCACCGGCTGCATCAAGAAGCACGGCTACACCGTG
GAGGTGCAGTTCGACGGCGACATCTGCAACACCATGCACTACACCAACTG
GACCCACATCTACATCTGCGAGGAGGCCAGCGTGACCGTGGTGGAGGGCC
AGGTGGACTACTACGGCCTGTACTACGTGCACGAGGGGCATCCGCACCTAC
TTCGTGCAGTTCAAGGACGACGCCGAGAAGTACAGCAAGAACAAGGTGTG
GGAGGTGCACGCCGCGGCCAGGTGATCCTGTGCCCCACCAGCGTGTTCA
GCAGCAACGAGGTGAGCAGCCCCGAGACCATCCGCCAGCACCTGGCCAAC
CACAGCGCCGCCACCCACACCAAGGCCGTGGCCCTGGGCACCGAGGAGAC
CCAGACCACCATCCAGCGCCCCCGCAGCGAGCCCGACACCGGCAACCCCTG
CCACACCACCAAGCTGCTGCACCGCGACAGCGTGGACAGCGCCCCCATCCT
GACCGCCTTCAACAGCAGCCACAAGGGCCGCATCAACTGCAACAGCAACA
CCACCCCCATCGTGACCTGAAGGGCGACGCCAACACCCTGAAGTGCCTGC
GCTACCGCTTCAAGAAGCACTGCAAGCTGTACACCGCCGTGAGCAGCACC
TGGCACTGGACCGGCCACAACGTGAAGCACAAGAGCGCCATCGTGACCCT
GACCTACGACAGCGAGTGGCAGCGCGACCAAGTTCCTGAGCCAGGTGAAGA
TCCCCAAGACCATCACCGTGAGCACCGGCTTCATGAGCATCTAA

4/31

FIGURE 4

SEQ.ID.NO.:4 Codon-Optimized HPV16E7-C24G,E26G Mutant:

ATGCACGGCGACACCCCCACCCTGCACGAGTACATGCTGGACCTGCAGCCC
GAGACCACCGACCTGTACGGCTACGGCCAGCTGAACGACAGCAGCGAGGA
GGAGGACGAGATCGACGGCCCCGCCGGCCAGGCCGAGCCCGACCGCGCCC
ACTACAACATCGTGACCTTCTGCTGCAAGTGCGACAGCACCCCTGCGCCTGT
GCGTGCAGAGCACCCACGTGGACATCCGCACCCTGGAGGACCTGCTGATG
GGCACCCCTGGGCATCGTGTGCCCCATCTGCAGCCAGAAGCCCTAA

5/31

FIGURE 5

SEQ.ID.NO.:5 Codon-Optimized HPV6a E7 Gene:

ATGCACGGCCGCCACGTGACCCTGAAGGACATCGTGCTGGACCTGCAGCC
TCCCGACCCCGTGGGCCTGCACTGCTACGAGCAGCTGGTGGACAGCAGCG
AGGACGAGGTGGACGAGGTGGACGGCCAGGACAGCCAGCCCCTGAAGCA
GCACTTCCAGATCGTGACCTGCTGCTGCGGCTGCGACAGCAACGTGCGCCT
GGTGGTGCAGTGCACCGAGACCGACATCCGCGAGGTGCAGCAGCTCCTGC
TGGGTACCCTGAACATCGTGTGCCCCATCTGCGCTCCCAAGACCTAA

6/31

FIGURE 6

SEQ.ID.NO.:6 Codon-Optimized HPV18 E7 Gene:

ATGCACGGCCCCAAGGCCACCCTGCAGGACATCGTGCTGCACCTGGAGCCC
CAGAACGAGATCCCCGTGGACCTGCTGTGCCACGAGCAGCTGAGCGACAG
CGAGGAGGAGAACGACGAGATCGACGGCGTGAACCACCAGCACCTGCCCCG
CTCGCAGGGCCGAGCCCCAGCGCCACACCATGCTGTGCATGTGCTGCAAGT
GCGAGGCCCCGCATCGAGCTGGTGGTGGAGAGCAGCGCTGACGACCTGCGC
GCCTTCCAGCAGCTGTTCTGAACACCCTGAGCTTCGTGTGCCCTGGTGC
GCCAGCCAGCAGTAA

7/31

FIGURE 7SEQ.ID.NO.:7 Codon-Optimized HPV6a E2 Gene:

ATGGAGGCCATCGCCAAGCGCCTGGACGCCTGCCAGGAGCAGCTGCTGGA
GCTGTACGAGGAGAACAGCACCGACCTGCACAAGCACGTGCTGCACTGGA
AGTGCAATGCGCCACGAGAGCGTGCTGTGTACAAGGCCAAGCAGATGGGC
CTGAGCCACATCGGCATGCAGGTGGTGCCTCCTCTGAAGGTGAGCGAGGC
CAAGGGCCACAACGCCATCGAGATGCAGATGCACCTCGAGAGCCTGCTGC
GCACCGAGTACAGCATGGAGCCCTGGACCCTGCAGGAGACCAGCTACGAG
ATGTGGCAGACCCCTCCCAAGCGCTGCTTCAAGAAGCGCGGCAAGACCGT
GGAGGTGAAGTTCGACGGCTGCGCCAACAACACCATGGACTACGTGGTGT
GGACCGACGTGTACGTGCAGGACAACGACACCTGGGTGAAGGTGCACAGC
ATGGTGGACGCCAAGGGCATCTACTACACCTGTGGCCAGTTCAAGACCTA
CTACGTGAACTTCGTGAAGGAGGCCGAGAAGTACGGCAGCACCAAGCACT
GGGAGGTGTGCTACGGCAGCACCGTGATCTGCAGCCCCGCTAGCGTGAGC
AGCACCAACCAGGAGGTGAGCATCCCCGAGAGCACCACTACACTCCCGCC
CAGACCAGCACCCCTGGTGAGCAGCAGCACCAAGGAGGACGCCGTGCAGAC
CCCTCCTCGCAAGCGCGCCCGCGGCGTGAGCAGAGCCCCTGCAACGCCCT
GTGCGTGGCCACATCGGCCCCGTGGATAGCGGCAACCACAACCTGATCA
CCAACAACCACGACCAGCACCGAGCGCCGCAACAACAGCAACAGCAGCGCC
ACTCCCATCGTGCAAGTTCAGGGCGAGAGCAACTGCCTGAAGTGCTTCCGC
TACCGCCTGAACGATCGCCACCGCCACCTGTTGACCTGATCAGCAGCACC
TGGCACTGGGCCAGCAGCAAGGCTCCCCACAAGCACGCCATCGTGACCGT
GACCTACGACAGCGAGGAGCAGCGCCAGCAGTTCCTGGACGTGGTGAAGA
TCCCTCCCACCATCAGCCACAAGCTGGGCTTCATGAGCCTGCACCTGCTGT
AA

8/31

FIGURE 8SEQ.ID.NO.:8 Codon-Optimized HPV18 E2 Gene:

ATGCAGACTCCCAAGGAGACCCTGAGCGAGCGCCTGAGCGCCCTGCAGGA
CAAGATCATCGACCACTACGAGAACGACAGCAAGGACATCGACAGCCAGA
TCCAGTACTGGCAGCTGATCCGCTGGGAGAACGCCATCTTCTTCGCCGCTC
GCGAGCACGGGATCCAGACCCTGAACCACCAGGTGGTGCCCGCCTACAAC
ATCAGCAAGAGCAAGGCCCAAGGCCATCGAGCTGCAGATGGCCCTGCA
GGGCCTGGCCAGAGCGCCTACAAGACCGAGGACTGGACCCTGCAGGACA
CCTGCGAGGAGCTGTGGAACACCGAGCCCACCCACTGCTTCAAGAAGGGA
GGCCAGACCGTGCAGGTGTACTTCGACGGCAACAAGGACAACTGCATGAA
CTACGTGGCCTGGGACAGCGTGTACTACATGACCGACGCCGGCACCTGGG
ACAAGACCGCCACCTGCGTGAGCCACCGCGGCCTGTACTACGTGAAGGAG
GGCTACAACACCTTCTACATCGAGTTCAAGAGCGAGTGCGAGAAGTACGG
CAACACCGGCACCTGGGAGGTGCACTTCGGCAACAACGTGATCGACTGCA
ACGACAGCATGTGCAGCACCAGCGACGACACCGTGAGCGCCACCCAGCTG
GTGAAGCAGCTGCAGCACACTCCCAGCCCCTACAGCAGCACCGTGAGCGT
GGGCACCGCCAAGACCTACGGCCAGACCAGCGCCGCCACTCGCCCTGGCCA
CTGCGGCCTGGCCGAGAAGCAGCACTGCGGGCCCGTGAACCCTCTGCTGG
GCGCCGCCACCGCCACCGGCAACAACAAGCGCCGCAAGCTGTGCAGCGGC
AACACCACTCCCATCATCCACCTGAAGGGCGACCGCAACAGCCTGAAGTG
CCTGCGGTACCGCCTGCGCAAGCACAGCGACCACTACCGCGACATCAGCA
GCACCTGGCACTGGACCGGCGCCGGGAACGAGAAGACCGGCATCCTGACC
GTGACCTACCACAGCGAGACCCAGCGCACCAAGTTCCTGAACACCGTGGC
CATCCCCGACAGCGTGCAGATCCTGGTGGGCTACATGACCATGTAA

9/31

FIGURE 9.

Comparison of protein expression of
native and synthetic HPV16 L1 genes





FIGURE 9 shows the results of immunoblot analysis of lysates of 293 cells transiently-transfected with native (lanes d, e, f) or synthetic (a, b, c) HPV 16 L1 sequences in the expression vector V1Jns

10/31

FIGURE 10. Immunoblot Analysis of 293 Cells Transiently-Transfected with Native (lane a, d) or Synthetic (lanes b, e) HPV16E1 Sequences in the Expression Vector V1Jns. Lane c is Mock Transfected Control.

Comparison of protein expression
of native and synthetic HPV 16 E1 genes




10

15

20

11/31

FIGURE 11. Immunoblot analysis of lysates of 293 cells transiently-transfected with native or synthetic HPV 16 E2 sequences in the expression vector V1Jns. Lane a is mock-infected; lane b is lacZ control; lane c contains a synthetic HPV16 E2 isolate #6; lane d contains synthetic HPV16 E2 isolate #11, and lane e has native HPV16 E2




- a. mock
- b. lacZ
- c. synthetic 16 E2 isolate 6
- d. synthetic 16 E2 isolate 11
- e native 16 E2

xmww98.75 16557-27

12/31

FIGURE 12

Comparison of protein expression of
native and synthetic HPV16 E7 genes




- a. mock
- b. lacZ
- c. synthetic HPV16 E7 isolate 2
- d. synthetic HPV16 E7 isolate 4
- e. native HPV16 E7

xm98.75 16557-27


13/31

FIGURE 13 shows the results of immunoblot analysis of lysates of 293 cells transiently-transfected with synthetic HPV6a E7 sequences in the expression vector V1Jns. Lanes b and c contain synthetic HPV6a E7 sequences; lane d contains a lacZ control, and lane a is a mock-transfected control



14/31

FIGURE 14. Immunoblot analysis of lysates of 293 cells transiently-transfected with synthetic HPV18 E7 sequences in the expression vector V1Jns. Lanes b, c, d, and e contain synthetic HPV18 E7 sequences; lane f contains synthetic HPV16 E7 as an antibody control, and lane a is a mock-transfected control



15/31

Expression of synthetic HPV 6 E2 gene




Figure 15. Expression of a synthetic gene encoding HPV 6 E2 protein. 293 cells were transfected with synthetic HPV 6 E2 or control plasmids or were mock transfected. Cell lysates were prepared 48 hr. later, fractionated by SDS PAGE and analyzed by immunoblotting using a goat anti- 6E2 antiserum as first antibody. a. 6 E2-5.4; b. 6E2-5.5; c. beta-gal; d. mock.

16/31

Expression of synthetic HPV 18 E2 gene




Figure 16. Expression of a synthetic gene encoding HPV 18 E2 protein. 293 cells were transfected with synthetic HPV 18 E2 or control plasmids or were mock transfected. Cell lysates were prepared 48 hr. later, fractionated by SDS PAGE and analyzed by immunoblotting using a goat anti- 18E2 antiserum as first antibody. a. beta-gal; b. mock; c. 18 E2-4.4; d. 18E2-4.5.

17/31

FIGURE 17

HPV16 L1 Gene-Building Oligomers

MN4A1 (SEQ.ID.NO:9) 5' ATG AGC CTG TGG CTG CCC AGC GAG GCC ACC
GTG TAC CTG CCT CCC GTG CCC GTG AGC AAG GTG GTG AGC ACC GAC
GAG TAC GTG GCC CGC ACC AAC ATC TAC TAC CAC GCC GGC ACC AGC
CGC CTG CTG 3'

MN4A3 (SEQ.ID.NO:10) 5' CGC ATC CAC CTG CCC GAC CCC AAC AAG TTC
GGC TTC CCC GAC ACA AGC TTC TAC AAC CCC GAC ACC CAG CGC CTG
GTG TGG GCC TGC GTG GGC GTG GAG GTG GGC CGC GGC CAG CCC CTG
GGC GTG GGC 3'

MN4A5 (SEQ.ID.NO:11) 5' GAG TGC ATC AGC ATG GAC TAC AAG CAG ACC
CAG CTG TGC CTG ATC GGC TGC AAG CCT CCC ATC GGC GAG CAC TGG
GGC AAG GGC AGC CCC TGC ACC AAC GTG GCC GTG AAC CCC GGC GAC
TGC CCT CCC 3'

MN4A7 (SEQ.ID.NO:12) 5' GCC AAC AAG AGC GAG GTG CCC CTG GAC ATC
TGC ACC AGC ATC TGC AAG TAC CCC GAC TAC ATC AAG ATG GTG AGC
GAG CCC TAC GGC GAC AGC CTG TTC TTC TAC CTG CGC CGC GAG CAG
ATG TTC GTG CGC 3'

MN4A9 (SEQ.ID.NO:13) 5' GCC AGC AGC AAC TAC TTC CCC ACT CCC AGC
GGC AGC ATG GTG ACC AGC GAC GCC CAA ATC TTC AAC AAG CCC TAC
TGG CTG CAG CGC GCC CAG GGC CAC AAC AAC GGC ATC TGC TGG GGC
AAC CAG CTG 3'

MN4A11 (SEQ.ID.NO:14) 5' GAG TAC CTG CGC CAC GGC GAG GAG TAC
GAC CTG CAG TTC ATC TTC CAG CTG TGC AAG ATC ACC CTG ACC GCC
GAC GTG ATG ACC TAC ATC CAC AGC ATG AAC AGC ACC ATC CTG GAG
GAC TGG AAC TTC GGC CTG 3'

MN4A13 (SEQ.ID.NO:15) 5' GCT CCC AAG GAG GAT CCC CTG AAG AAG
TAC ACC TTC TGG GAG GTG AAC CTG AAG GAG AAG TTC AGC GCC GAC
CTG GAC CAG TTC CCC CTG GGC CGC AAG TTC CTG CTG CAG GCC GGC
CTG AAG GCC AAG CCC AAG 3'

MN4A2 (SEQ.ID.NO:16) 5' GTT GGG GTC GGG CAG GTG GAT GCG GAA CAC
GCG GTA CTG CAG GCC GCT CAC CTT GGG CAC CAG GAT CTT GTT GTT
GTT GGG CTT CTT GAT GGG GAA GTA GGG GTG GCC CAC GGC CAG CAG
GCG GCT GGT GCC GGC 3'

18/31

FIG. 17, CTD. 2/3

MN4A4 (SEQ.ID.NO:17) 5' CTT GTA GTC CAT GCT GAT GCA CTC GCG GTT
GTC CAC GCC GGC GTT GGC GGC GTA GGC GCT GGC GTT CTC GGT GTC
GTC CAG CTT GTT CAG CAG GGG GTG GCC GCT GAT GCC CAC GCC CAG
GGG CTG GCC GCG 3'

MN4A6 (SEQ.ID.NO:18) 5' CAG GGG CAC CTC GCT CTT GTT GGC CTG CAG
GGT GGT GAA GTC CAT GGC GCC GAA GCC GGT GTC CAC CAT GTC GCC
GTC CTG GAT CAC GGT GTT GAT CAG CTC CAG GGG AGG GCA GTC GCC
GGG GTT CAC 3'

MN4A8 (SEQ.ID.NO:19) 5' GGG AGT GGG GAA GTA GTT GCT GCT GGC CAG
GTT GGC GGT GCT GCC GCT GCC CTT GAT GTA CAG GTC GTC GGG CAC
GTT CTC GCC CAC GGC GCC GGC GCG GTT GAA CAG GTG GCG CAC GAA
CAT CTG CTC GCG 3'

MN4A10 (SEQ.ID.NO:20) 5' CTC CTC GCC GTG GCG CAG GTA CTC CTT GAA
GTT GGT GTT CTT GTA GGT GGT CTC GCT GGT GCT GAT GGC GGC GCA
CAG GCT CAT GTT GGT GCT GCG GGT GGT GTC CAC CAC GGT CAC GAA
CAG CTG GTT GCC CCA GCA GAT GCC 3'

MN4A12 (SEQ.ID.NO:21) 5' CTT CAG GGG ATC CTC CTT GGG AGC GGG
AGG GGT GTG CTT CTG GCA GGC GAT GGC CTG GCT GGT CAC GAA GCG
GTA GGT GTC CTC CAG GGT ACC GCC GGG AGG GGG CTG CAG GCC GAA
GTT CCA GTC CTC CAG 3'

MN4A14 (SEQ.ID.NO:22) 5' CAC TAG AGA TCT GAA TTC TTA CAG CTT GCG
CTT CTT GCG CTT GGC GGT GGT GCT GGT GCT GCT GGT GGT GGG GGT
GGC CTT GCG CTT GCC CAG GGT GAA CTT GGG CTT GGC CTT CAG GCC
GGC 3'

MN595 (SEQ.ID.NO:23) 5' CGC GGC CAG CCC CTG GGC GTG 3'

MN596 (SEQ.ID.NO:24) 5' GCC CAC GCC CAG GGG CTG GCC GCG 3'

MN597 (SEQ.ID.NO:25) 5' GCC AAC AAG AGC GAG GTG CCC 3'

MN598 (SEQ.ID.NO:26) 5' CAG GGG CAC CTC GCT CTT GTT GGC 3'

MN599 (SEQ.ID.NO:27) 5' GCC AGC AGC AAC TAC TTC CCC AC 3'

MN600 (SEQ.ID.NO:28) 5' GGG AGT GGG GAA GTA GTT GCT GC 3'

19/31

FIG. 17, CTD. 3/3

MN601 (SEQ.ID.NO:29) 5' CTG GAG GAC TGG AAC TTC GGC CTG 3'

MN602 (SEQ.ID.NO:30) 5' CAG GCC GAA GTT CCA GTC CTC CAG 3'

MN603 (SEQ.ID.NO:31) 5' CAC TAG AGA TCT GAA TTC TTA CAG C 3'

MN604 (SEQ.ID.NO:32) 5' CAT CTC AGA TCT GCC ACC ATG AGC CTG TGG
CTG CCC AG 3'

20/31

FIGURE 18

HPV16E1 Gene-building Oligomers

MN605 (SEQ.ID.NO:33) 5' ATG GCC GAC CCC GCC GGC ACC AAC GGC GAG
GAG GGC ACC GGC TGC AAC GGC TGG TTC TAC GTG GAG GCC GTG GTG
GAG AAG AAG ACC GGC GAC GCC ATC AGC GAC GAC GAG AAC GAG
AAC GAC AGC GAC 3'

MN606 (SEQ.ID.NO:34) 5' GTG CTG CTT GGC CTC CTG GGC GGT GAA CAG
GGC GTG GGC GGT CTC GGT CTC GGC CTG GGT CAG GTA GTC GTT GTC
GTT CAC GAT GAA GTC CAC CAG GTC CTC GCC GGT GTC GCT GTC GTT
CTC GTT CTC GTC 3'

MN607(SEQ.ID.NO:35) 5' GCC CAG GAG GCC AAG CAG CAC CGC GAC GCC
GTG CAG GTG CTG AAG CGC AAG TAC CTG GGC AGC CCC CTG AGC GAC
ATC AGC GGC TGC GTC GAC AAC AAC ATC AGC CCC CGC CTG AAG GCC
ATC TGC ATC GAG 3'

MN608 (SEQ.ID.NO:36) 5' CTC GTG GCG GCC CTC CAC CTG CAG CAT CTG
CTG GGT CTC CAC CTC GGT GTT GCC GTA GCC GCT GTC CTC GCT CTC
GAA CAG GCG GCG CTT GGC GGC GCG GCT CTG CTT CTC GAT GCA GAT
GGC CTT CAG GC 3'

MN609 (SEQ.ID.NO:37) 5' CAG GTG GAG GGC CGC CAC GAG ACC GAG ACC
CCC TGC AGC CAG TAC AGC GGC GGC AGC GGC GGC GGC TGC AGC CAG
TAC AGC AGC GGC AGC GGC GGC GAG GGC GTG AGC GAG CGC CAC ACC
ATC TGC CAG ACC 3'

MN610 (SEQ.ID.NO:38): 5' CTT GAA GGG GCG CAC CAG CTC GCT GAA GCT
CAC GCC GTA CAG CTC CTT GAA CTT GGC CAG CAT GGC GGC CTT GGC
GTT GCT GGT CTT CAG CAC GTT CAG GAT GTT GGT CAG AGG GGT CTG
GCA GAT GGT GTG GCG 3'

MN611 (SEQ.ID.NO:39) 5' GAG CTG GTG CGC CCC TTC AAG AGC AAC AAG
AGC ACC TGC TGC GAC TGG TGC ATC GCC GCC TTC GGC CTG ACC CCC
AGC ATC GCC GAC AGC ATC AAG ACC CTG CTG CAG CAG TAC TGC CTG
TAC CTG CAC ATC CAG 3'

MN612 (SEQ.ID.NO:40) 5' CAT GGG GCT CAC GCA CAG CAG CTT GCT CAG
CAG CTT CTC GAT GGT CTC GCG GTT CTT GCC GCA CTT GTA GCG CAC
CAG CAG CAG CAC CAC CAT GCC CCA GCT GCA GGC CAG GCT CTG GAT
GTG CAG GTA CAG GCA G 3'

FIGURE 18, CTD. 2/3

MN613 (SEQ.ID.NO:41) 5' CTG CTG TGC GTG AGC CCC ATG TGC ATG ATG
ATC GAG CCT CCC AAG CTT CGC AGC ACC GCC GCC GCC CTG TAC TGG
TAC AAG ACC GGC ATC AGC AAC ATC AGC GAG GTG TAC GGC GAC ACC
CCC GAG TGG ATC 3'

MN614 (SEQ.ID.NO:42) 5' GGC GAT CTC GCT GTC GTC CAC GAT GTC GTT
GTC GTA GGC CCA CTG CAC CAT CTG GCT CAG CTC GAA GGT GCA GTC
GTT GAA GCT GTG CTG CAG CAC GGT CTG GCG CTG GAT CCA CTC GGG
GGT GTC GCC 3'

MN615 (SEQ.ID.NO:43): 5' GTG GAC GAC AGC GAG ATC GCC TAC AAG TAC
GCC CAG CTG GCC GAC ACC AAC AGC AAC GCC AGC GCC TTC CTG AAG
AGC AAC AGC CA GGC CAA GAT CGT GAA GGA CTG CGC CAC CAT GTG
CCG CCA CTA C 3'

MN616 (SEQ.ID.NO:44) 5' GTA GCG CAG GAA CAT CAC GAT CTG CTT GCG
GTC GCC GCC GTC GTC CAC GCG GTC GCA GCG GTA CTT GAT CCA CTG
GCT CAT GCT CAT CTG CTT CTT CTC GGC GCG CTT GTA GTG GCG GCA
CAT GGT GGC 3'

MN617 (SEQ.ID.NO:45) 5' CAG ATC GTG ATG TTC CTG CGC TAC CAG GGC
GTG GAA TTC ATG AGC TTC CTG ACC GCC CTG AAG CGC TTC CTG CAG
GGC ATC CCC AAG AAG AAC TGC ATC CTG CTG TAC GGC GCC GCC AAC
ACC GAC AAG 3'

MN618 (SEQ.ID.NO:46) 5' GCC GAT CTT GGC GTC GGC CAG GGG CTG CAG
CCA GAA GTG GCT CTT GCT GTT CAC GAA GCA GAT CAC GCT GCC CTG
CAG GAA CTT CAT CAG GCT CAT GCC GAA CAG GCT CTT GTC GGT GTT
GGC GGC GCCG 3'

MN619 (SEQ.ID.NO:47) 5' CTG GCC GAC GCC AAG ATC GGC ATG CTG GAC
GAC GCC ACC GTG CCC TGC TGG AAC TAC ATC GAC GAC AAC CTG CGC
AAC GCC CTG GAC GGC AAC CTG GTG AGC ATG GAC GTG AAG CAC CGC
CCC CTG GTG 3'

MN620 (SEQ.ID.NO:48) 5' GAA CTC GTT GGG GAA GGT GAA CAC CAC CAG
GCG GTT GTG CAG GTA GGG CCA GCG GCT GTC GGT GCC GGC GTT GAT
GTT GCT GGT GAT CAG CAG GGG AGG GCA CTT CAG CTG CAC CAG GGG
GCG GTG CTT CAC 3'

22/31

FIGURE 18, CTD 3/3

MN621 (SEQ.ID.NO:49) 5' GTG TTC ACC TTC CCC AAC GAG TTC CCC TTC
GAC GAG AAC GGT AAC CCC GTG TAC GAG CTG AAC GAC AAG AAC TGG
AAG AGC TTC TTC AGC CGC ACC TGG AGC CGC CTG AGC CTG CAC GAG
GAC GAG 3'

MN622 (SEQ.ID.NO:50) 5' CAT GAG AGA TCT TTA CAG GGT GTT GGT GTT
CTG GCC GCT CAC GCA CTT GAA GGT GGG CAG GCT GTC GCC GTC GTT
CTC CTT GTC CTC GTC CTC GTG CAG GCT CAG 3'

MN623 (SEQ.ID.NO:51) 5' GCC TGA AGG CCA TCT GCA TCG AG 3'

MN624 (SEQ.ID.NO:52) 5' CTC GAT GCA GAT GGC CTT CAG GC 3'

MN625 (SEQ.ID.NO:53) 5' GAG CTG GTG CGC CCC TTC AAG 3'

MN626 (SEQ.ID.NO:54) 5' CTT GAA GGG GCG CAC CAG CTC 3'

MN627 (SEQ.ID.NO:55) 5' CTG CTG TGC GTG AGC CCC ATG 3'

MN628 (SEQ.ID.NO:56) 5' CAT GGG GCT CAC GCA CAG CAG 3'

MN629 (SEQ.ID.NO:57) 5' GCC ACC ATG TGC CGC CAC TAC 3'

MN630 (SEQ.ID.NO:58) 5' GTA GTG GCG GCA CAT GGT GGC 3'

MN631 (SEQ.ID.NO:59) 5' CTG GCC GAC GCC AAG ATC GGC 3'

MN632 (SEQ.ID.NO:60) 5' GCC GAT CTT GGC GTC GGC CAG 3'

MN633 (SEQ.ID.NO:61) 5' GTG TTC ACC TTC CCC AAC GAG TTC 3'

MN634 (SEQ.ID.NO:62) 5' GAA CTC GTT GGG GAA GGT GAA CAC 3'

MN635 (SEQ.ID.NO:63) 5' CAT GAG AGA TCT TTA CAG GGT GTT G 3'

MN636 (SEQ.ID.NO:64) 5' CAT CTC AGA TCT GCC ACC ATG GCC GAC CCC
GCC GGC AC 3'

23/31

FIGURE 19

Oligonucleotides used in the generation of synthetic HPV 16 E2

13856-307-2A (SEQ.ID.NO:65) 5' ATG GAG ACC CTG TGC CAG CGC CTG AAC
GTG TGC CAG GAC AAG ATC CTG ACC CAC TAC GAG AAC GAC AGC ACC
GAC CTG CGC GAC CAC ATC GAC TAC TGG 3'

13856-307-2C (SEQ.ID.NO:66) 5' CCA CCA GGT GGT GCC CAC CCT GGC CGT
GAG CAA GAA CAA GGC CCT GCA GGC CGC CGA GCT GCA GCT GAC CCT
GGA GAC GAT CTA CAA CAG CCA GTA CAG CAA CG 3'

13856-307-2E (SEQ.ID.NO:67) 5' CCG GCT GCA TCA AGA AGC ACG GCT ACA
CCG TGG AGG TGC AGT TCG ACG GCG ACA TCT GCA ACA CCA TGC ACT
ACA CCA ACT GGA CCC ACA TTT ACA TCT GTG AGG AGG 3'

13856-307-2G (SEQ.ID.NO:68) 5' CGT GCA CGA GGG GAT CCG CAC CTA CTT
CGT GCA GTT CAA GGA CGA CGC CGA GAA GTA CAG CAA GAA CAA GGT
GTG GGA GGT GCA CGC CGG AGG CCA GGT GAT CC 3'

13856-307-2I (SEQ.ID.NO:69) 5' GGC CAA CCA CAG CGC CGC CAC CCA CAC
CAA GGC CGT GGC CCT GGG CAC CGA GGA GAC CCA GAC CAC AAT CCA
GCG CCC TCG CAG CGA GCC CGA CAC CGG CAA CCC CTG CC 3'

13856-307-2K (SEQ.ID.NO:70) 5' GCC ACA AGG GCC GGA TCA ACT GCA ACA
GCA ACA CCA CCC CTA TCG TGC ACC TGA AGG GCG ACG CCA ACA CCC
TGA AGT GCC TGC GGT ACC GCT TCA AGA AGC ACT GC 3'

13856-307-2B (SEQ.ID.NO:71) 5' CCA GGG TGG GCA CCA CCT GGT GGT TGA
TGT GCT TGA AGC CCA TCT CGC GGG CCT TGT AGT AGA TGG CGC AGG
CCA GGC GCA TGT GCT TCC AGT AGT CGA TGT GGT CGC GCA GG 3'

13856-307-2D (SEQ.ID.NO:72) 5' GCC GTG CTT CTT GAT GCA GCC GGT AGG
GGC GGT CAG GTA CAC CTC CAG GCT CAC GTC CTG CAG GGT CCA CTT
CTC GTT GCT GTA CTG GCT GTT GTA GAT CG 3'

13856-307-2F (SEQ.ID.NO:73) 5' GGT GCG GAT CCC CTC GTG CAC GTA GTA
CAG GCC GTA GTA GTC CAC CTG GCC CTC CAC CAC GGT CAC GCT GGC
CTC CTC ACA GAT GTA AAT GTG GGT CC 3'

13856-307-2H (SEQ.ID.NO:74) 5' GGG TGG CGG CGC TGT GGT TGG CCA GGT
GCT GGC GGA TCG TCT CGG GGC TGC TCA CCT CGT TGC TGC TGA ACA
CGC TGG TGG GGC ACA GGA TCA CCT GGC CTC CGG CGT GC 3'

24/31

FIGURE 19, CTD. 2/2

13856-307-2J (SEQ.ID.NO:75) 5' GCA GTT GAT CCG GCC CTT GTG GCT GCT
GTT GAA GGC GGT CAG GAT AGG GGC GCT GTC GAC GCT GTC GCG GTG
CAG CAG CTT GGT GGT GTG GCA GGG GTT GCC GGT GTC GGG 3'

13856-307-2L (SEQ.ID.NO:76) 5' CGT AGG TCA GGG TCA CGA TAG CGC TCT
TGT GCT TCA CGT TGT GGC CGG TCC AGT GCC AGG TGC TGC TCA CGG
CGG TGT ACA GCT TGC AGT GCT TCT TGA AGC GGT ACC GC 3'

13856-307-2M (SEQ.ID.NO:77) 5' TTT AGA TGC TCA TGA AGC CGG TGC TCA
CGG TGA TGG TCT TGG GGA TCT TCA CCT GGC TCA GGA ACT GGT CGC
GCT GCC ACT CGC TGT CGT AGG TCA GGG TCA CGA TAG CGC 3'

13856-307-2PA (SEQ.ID.NO:78) 5' CGA GCT GAT ATC GAA TTC AGA TCT
GCC ACC ATG GAG ACC CTG TGC CAG CG 3'

13856-307-2PM (SEQ.ID.NO:79) 5' GGT TGC AGA TCT AGA CTC GAG TTT
AGA TGC TCA TGA AGC CGG TGC 3'

13856-307-2PE (SEQ.ID.NO:80) 5' CCG GCT GCA TCA AGA AGC ACG 3'

13856-307-2PI (SEQ.ID.NO:81) 5' GGC CAA CCA CAG CGC CGC C 3'

13856-307-2PD (SEQ.ID.NO:82) 5' GCC GTG CTT CTT GAT GCA GCC 3'

13856-307-2PH (SEQ.ID.NO:83) 5' GGG TGG CGG CGC TGT GG 3'

13856-307-2PL (SEQ.ID.NO:84) 5' CGT AGG TCA GGG TCA CGA TAG C 3'

25/31

FIGURE 20

Oligonucleotides used in the generation of synthetic HPV 16 E7.

13856-307-7A (SEQ.ID.NO:85) 5' GGC CGG AGA TCT GAT ATC GAA TTC GCC
ACC ATG CAC GGC GAC ACC CCC ACC CTG CAC GAG TAC ATG CTG GAC
CTG CAG CCC GAG ACC ACC GAC CTG TAC GGC TAC GGC C 3'

13856-307-7C (SEQ.ID.NO:86) 5' GCC GAG CCC GAC CGC GCC CAC TAC AAC
ATC GTG ACC TTC TGC TGC AAG TGC GAC AGC ACC CTG CGC CTG TGC
GTG CAG AGC ACC CAC GTC GAC ATC CGC ACC CTG G 3'

13856-307-7B (SEQ.ID.NO:87) 5' GGG CGC GGT CGG GCT CGG CCT GGC CGG
CGG GGC CGT CGA TCT CGT CCT CTT CCT CGC TGC TGT CGT TCA GCT
GGC CGT AGC CGT ACA GGT CGG TGG 3'

13856-307-7D (SEQ.ID.NO:88) 5' CCG CGG CAG ATC TAG ACT CGA GTT TAG
GGC TTC TGG CTG CAG ATT GGG CAC ACG ATT CCC AGG GTG CCC ATC
AGC AGG TCC TCC AGG GTG CGG ATG TCG ACG TGG G 3'

13856-307-7PA (SEQ.ID.NO:89) 5' GGC CGG AGA TCT GAT ATC GAA TTC G 3'

13856-307-7PD (SEQ.ID.NO:90) 5' CCG CGG CAG ATC TAG ACT CG 3'

26/31

FIGURE 21

Oligonucleotides Used for Construction of HPV6a E7 Gene**A. DNA Template Oligos**

LS207 (105-mer) (SEQ.ID.NO:91) 5' GTC ACA GAT CTG ATA TCG AAT TCC
ACC ATG CAC GGC CGC CAC GTG ACC CTG AAG GAC ATC GTG CTG GAC
CTG CAG CCT CCC GAC CCC GTG GGC CTG CAC TGC TAC 3'

LS208 (105-mer) (SEQ.ID.NO:92) 5' CTG GAA GTG CTG CTT CAG GGG CTG
GCT GTC CTG GCC GTC CAC CTC GTC CAC CTC GTC CTC GCT GCT GTC
CAC CAG CTG CTC GTA GCA GTG CAG GCC CAC GGG GTC 3'

LS209 (107-mer) (SEQ.ID.NO:93) 5' CCA GCC CCT GAA GCA GCA CTT CCA
GAT CGT GAC CTG CTG CTG CGG CTG CGA CAG CAA CGT GCG CCT GGT
GGT GCA GTG CAC CGA GAC CGA CAT CCG CGA GGT GCA GC 3'

LS210 (102-mer) (SEQ.ID.NO:94) 5' CAG TCA GAT CTA GAG ATA TCT TTA
GGT CTT GGG AGC GCA GAT GGG GCA CAC GAT GTT CAG GGT ACC CAG
CAG GAG CTG CTG CAC CTC GCG GAT GTC GGT CTC 3'

B. PCR Amplification Primers

LS211 (24-mer) (SEQ.ID.NO:95) 5' GTC ACA GAT CTG ATA TCG AAT TCC 3'

LS212 (26-mer) (SEQ.ID.NO:96) 5' CAG TCA GAT CTA GAG ATA TCT TTA GG
3'

27/31

FIGURE 22

Oligonucleotides Used for Construction of HPV18 E7 Gene**A. DNA Template Oligos**

LS201 (109-mer) (SEQ.ID.NO:97) 5' GTC ACA GAT CTG ATA TCG AAT TCC ACC
ATG CAC GGC CCC AAG GCC ACC CTG CAG GAC ATC GTG CTG CAC CTG
GAG CCC CAG AAC GAG ATC CCC GTG GAC CTG CTG TGC C 3'

LS202 (111-mer) (SEQ.ID.NO:98) 5' GGG CTC GGC CCT GCG AGC GGG CAG
GTG CTG GTG GTT CAC GCC GTC GAT CTC GTC GTT CTC CTC CTC GCT
GTC GCT CAG CTG CTC GTG GCA CAG CAG GTC CAC GGG GAT CTC 3'

LS203 (108-mer) (SEQ.ID.NO:99) 5' GCC CGC TCG CAG GGC CGA GCC CCA
GCG CCA CAC CAT GCT GTG CAT GTG CTG CAA GTG CGA GGC CCG CAT
CGA GCT GGT GGT GGA GAG CAG CGC TGA CGA CCT GCG CGC 3'

LS204 (109-mer) (SEQ.ID.NO:100) 5' CAG TCA GAT CTA GAG ATA TCT TTA
CTG CTG GCT GGC GCA CCA GGG GCA CAC GAA GCT CAG GGT GTT CAG
GAA CAG CTG CTG GAA GGC GCG CAG GTC GTC AGC GCT GCT C 3'

B. PCR Amplification Primers

LS205 (26-mer) (SEQ.ID.NO:101) 5' GTC ACA GAT CTG ATA TCG AAT TCC AC
3'

LS206 (27-mer) (SEQ.ID.NO:102) 5' CAG TCA GAT CTA GAG ATA TCT TTA
CTG 3'

28/31

FIGURE 23

Oligonucleotides used in the construction of HPV6 E2

6A 1-84 (90mer) (SEQ.ID.NO:103) 5' GAA TTC AGA TCT GAT ATC ACC ATG
GAG GCC ATC GCC AAG CGC CTG GAC GCC TGC CAG GAG CAG CTG CTG
GAG CTG TAC GAG GAG AAC AGC 3'

6B 65-157 (92mer) (SEQ.ID.NO:104) 5' CCT TGT ACA GCA GCA CGC TCT
CGT GGC GCA TGC ACT TCC AGT GCA GCA CGT GCT TGT GCA GGT CGG
TGC TGT TCT CCT CGT ACA GCT CCA GC 3'

6C 132-227 (96mer) (SEQ.ID.NO:105) 5' CCA CGA GAG CGT GCT GCT GTA
CAA GGC CAA GCA GAT GGG CCT GAG CCA CAT CGG CAT GCA GGT GGT
GCC TCC TCT GAA GGT GAG CGA GGC CAA GGG 3'

6D 202-304 (103mer) (SEQ.ID.NO:106) 5' GCA GGG TCC AGG GCT CCA TGC
TGT ACT CGG TGC GCA GCA GGC TCT CGA GGT GCA TCT GCA TCT CGA
TGG CGT TGT GGC CCT TGG CCT CGC TCA CCT TCA GAG G 3'

6E 276-373 (98mer) (SEQ.ID.NO:107) 5' CGA GTA CAG CAT GGA GCC CTG
GAC CCT GCA GGA GAC CAG CTA CGA GAT GTG GCA GAC CCC TCC CAA
GCG CTG CTT CAA GAA GCG CGG CAA GAC CGT GG 3'

6F 347-448 (102mer) (SEQ.ID.NO:108) 5' CGT TGT CCT GCA CGT ACA CGT
CGG TCC ACA CCA CGT AGT CCA TGG TGT TGT TGG CGC AGC CGT CGA ACT
TCA CCT CCA CGG TCT TGC CGC GCT TCT TGA AGC 3'

6G 425-526 (102mer) (SEQ.ID.NO:109) 5' CCG ACG TGT ACG TGC AGG ACA
ACG ACA CCT GGG TGA AGG TGC ACA GCA TGG TGG ACG CCA AGG GCA
TCT ACT ACA CCT GTG GCC AGT TCA AGA CCT ACT ACG 3'

6H 495-586 (92mer) (SEQ.ID.NO:110) 5' GCT GCC GTA GCA CAC CTC CCA
GTG CTT GGT GCT GCC GTA CTT CTC GGC CTC CTT CAC GAA GTT CAC GTA
GTA GGT CTT GAA CTG GCC ACA GG 3'

6I 500-591 (94mer) (SEQ.ID.NO:111) 5' GCA CTG GGA GGT GTG CTA CGG
CAG CAC CGT GAT CTG CAG CCC CGC TAG CGT GAG CAG CAC CAC CCA
GGA GGT GAG CAT CCC CGA GAG CAC CAC C 3'

6J 636-732 (97mer) (SEQ.ID.NO:112) 5' GCG AGG AGG GGT CTG CAC GGC
GTC CTC CTT GGT GCT GCT GCT CAC CAG GGT GCT GGT CTG GGC GGG
AGT GTA GGT GGT GCT CTC GGG GAT GCT CAC C 3'

29/31

FIGURE 23, CTD. 2/2

6K 708-804 (97mer) (SEQ.ID.NO:113) 5' GGA CGC CGT GCA GAC CCC TCC
TCG CAA GCG CGC CCG CGG CGT GCA GCA GAG CCC CTG CAA CGC CCT
GTG CGT GGC CCA CAT CGG CCC CGT GGA CAG C 3'

6L 780-873 (94mer) (SEQ.ID.NO:114) 5' GGC GCT GCT GTT GCT GTT GTT
GCG GCG CTG GTG CTG GTC GTG GTT GTT GGT GAT CAG GTT GTG GTT
GCC GCT GTC CAC GGG GCC GAT GTG GGC C 3'

6M 849-943 (95mer) (SEQ.ID.NO:115) 5' CCG CAA CAA CAG CAA CAG CAG
CGC CAC TCC CAT CGT GCA GTT CCA GGG CGA GAG CAA CTG CCT GAA
GTG CTT CCG CTA CCG CCT GAA CGA TCG CC 3'

6N 917-1012 (96mer) (SEQ.ID.NO:116) 5' CGT GCT TGT GGG GAG CCT TGC
TGC TGG CCC AGT GCC AGG TGC TGC TGA TCA GGT CGA ACA GGT GGC
GGT GGC GAT CGT TCA GGC GGT AGC GGA AGC 3'

6O 989-1083 (95mer) (SEQ.ID.NO:117) 5' GCA GCA AGG CTC CCC ACA AGC
ACG CCA TCG TGA CCG TGA CCT ACG ACA GCG AGG AGC AGC GCC AGC
AGT TCC TGG ACG TGG TGA AGA TCC CTC CC 3'

6P 1059-1154 (96mer) (SEQ.ID.NO:118) 5' CTC GAG AGA TCT CCC GGG TCT
AGA GCT TAC AGC AGG TGC AGG CTC ATG AAG CCC AGC TTG TGG CTG
ATG GTG GGA GGG ATC TTC ACC ACG TCC AGG 3'

6PA 25mer (SEQ.ID.NO:119) 5' GAA TTC AGA TCT GAT ATC ACC ATG G 3'

6PD 21mer (SEQ.ID.NO:120) 5' GCA GGG TCC AGG GCT CCA TGC 3'

6PE 25mer (SEQ.ID.NO:121) 5' CGA GTA CAG CAT GGA GCC CTG GAC C 3'

6PH 25mer (SEQ.ID.NO:122) 5' GCT GCC GTA GCA CAC CTC CCA GTG C 3'

6PI 21mer (SEQ.ID.NO:123) 5' GCA CTG GGA GGT GTG CTA CGG 3'

6PL 23mer (SEQ.ID.NO:124) 5' GGC GCT GCT GTT GCT GTT GTT GC 3'

6PM 22mer (SEQ.ID.NO:125) 5' CCG CAA CAA CAG CAA CAG CAG C 3'

6PP 26mer (SEQ.ID.NO:126) 5' CTC GAG AGA TCT CCC GGG TCT AGA GC 3'

30/31

FIGURE 24

Oligonucleotides used to construct HPV18 E2

18A 1-97 (97mer) (SEQ.ID.NO:127) 5' GAA TTC AGA TCT GAT ATC ACC ATG
CAG ACT CCC AAG GAG ACC CTG AGC GAG CGC CTG AGC GCC CTG CAG
GA CAA GAT CAT CGA CCA CTA CGA GAA CG 3'

18B 69-166 (98mer) (SEQ.ID.NO:128) 5' CGA AGA AGA TGG CGT TCT CCC
AGC GGA TCA GCT GCC AGT ACT GGA TCT GGC TGT CGA TGT CCT TGC
TGT CGT TCT CGT AGT GGT CGA TGA TCT TGT CC 3'

18C 141-234 (94mer) (SEQ.ID.NO:129) 5' CCG CTG GGA GAA CGC CAT CTT
CTT CGC CGC TCG CGA GCA CGG GAT CCA GAC CCT GAA CCA CCA GGT
GGT GCC CGC CTA CAA CAT CAG CAA GAG C 3'

18D 211-304 (94mer) (SEQ.ID.NO:130) 5' CCT CGG TCT TGT AGG CGC TCT
GGG CCA GGC CCT GCA GGG CCA TCT GCA GCT CGA TGG CCT TGT GGG
CCT TGC TCT TGC TGA TGT TGT AGG CGG G 3'

18E 281-371 (91mer) (SEQ.ID.NO:131) 5' CCC AGA GCG CCT ACA AGA CCG
AGG ACT GGA CCC TGC AGG ACA CCT GCG AGG AGC TGT GGA ACA CCG
AGC CCA CCC ACT GCT TCA AGA AGG G 3'

18F 348-441 (94mer) (SEQ.ID.NO:132) 5' GCT GTC CCA GGC CAC GTA GTT
CAT GCA GTT GTC CTT GTT GCC GTC GAA GTA CAC CTG CAC GGT CTG
GCC TCC CTT CTT GAA GCA GTG GGT GGG C 3'

18G 416-505 (90mer) (SEQ.ID.NO:133) 5' GCA TGA ACT ACG TGG CCT GGG
ACA GCG TGT ACT ACA TGA CCG ACG CCG GCA CCT GGG ACA AGA CCG
CCA CCT GCG TGA GCC ACC GCG GCC 3'

18H 481-572 (92mer) (SEQ.ID.NO:134) 5' CCG TAC TTC TCG CAC TCG CTC
TTG AAC TCG ATG TAG AAG GTG TTG TAG CCC TCC TTC ACG TAG TAC
AGG CCG CGG TGG CTC ACG CAG GTG GC 3'

18I 543-636 (94mer) (SEQ.ID.NO:135) 5' CGA GTT CAA GAG CGA GTG CGA
GAA GTA CGG CAA CAC CGG CAC CTG GGA GGT GCA CTT CGG CAA CAA
CGT GAT CGA CTG CAA CGA CAG CAT GTG C 3'

18J 609-708 (100mer) (SEQ.ID.NO:136) 5' GCT GTA GGG GCT GGG AGT GTG
CTG CAG CTG CTT CAC CAG CTG GGT GGC GCT CAC GGT GTC GTC GCT
GGT GCT GCA CAT GCT GTC GTT GCA GTC GAT CAC G 3'

31/31

FIGURE 24, CTD. 2/2

18K 687-779 (93mer) (SEQ.ID.NO:137) 5' GCA CAC TCC CAG CCC CTA CAG
CAG CAC CGT GAG CGT GGG CAC CGC CAA GAC CTA CGG CCA GAC CAG
CGC CGC CAC TCG CCC TGG CCA CTG CGG 3'

18L 758-853 (96mer) (SEQ.ID.NO:138) 5' GCT TGT TGT TGC CGG TGG CGG
TGG CGG CGC CCA GCA GAG GGT TCA CGG GCC CGC AGT GCT GCT TCT
CGG CCA GGC CGC AGT GGC CAG GGC GAG TGG 3'

18M 829-925 (97mer) (SEQ.ID.NO:139) 5' GCC ACC GCC ACC GGC AAC AAC
AAG CGC CGC AAG CTG TGC AGC GGC AAC ACC ACT CCC ATC ATC CAC
CTG AAG GGC GAC CGC AAC AGC CTG AAG TGC C 3'

18N 900-996 (97mer) (SEQ.ID.NO:140) 5' GGC GCC GGT CCA GTG CCA GGT
GCT GCT GAT GTC GCG GTA GTG GTC GCT GTG CTT GCG CAG GCG GTA
CCG CAG GCA CTT CAG GCT GTT GCG GTC GCC C 3'

18O 974-1072 (99mer) (SEQ.ID.NO:141) 5' GCA CCT GGC ACT GGA CCG GCG
CCG GGA ACG AGA AGA CCG GCA TCC TGA CCG TGA CCT ACC ACA GCG
AGA CCC AGC GCA CCA AGT TCC TGA ACA CCG TGG 3'

18P 1048-1145 (98mer) (SEQ.ID.NO:142) 5' CTC GAG AGA TCT CCC GGG TCT
AGA GCT TAC ATG GTC ATG TAG CCC ACC AGG ATC TGC ACG CTG TCG
GGG ATG GCC ACG GTG TTC AGG AAC TTG GTG CG 3'

18PA 25mer (SEQ.ID.NO:143) 5' GAA TTC AGA TCT GAT ATC ACC ATG C
3'

18PD 23mer (SEQ.ID.NO:144) 5' CCT CGG TCT TGT AGG CGC TCT GG 3'

18PE 21mer (SEQ.ID.NO:145) 5' CCC AGA GCG CCT ACA AGA CCG 3'

18PH 21mer (SEQ.ID.NO:146) 5' CCG TAC TTC TCG CAC TCG CTC 3'

18PI 20mer (SEQ.ID.NO:147) 5' CGA GTT CAA GAG CGA GTG CG 3'

18PL 21mer (SEQ.ID.NO:148) 5' GCT TGT TGT TGC CGG TGG CGG 3'

18PM 25mer (SEQ.ID.NO:149) 5' GCC ACC GCC ACC GGC AAC AAC AAG C 3'

18PP 26mer (SEQ.ID.NO:150) 5' CTC GAG AGA TCT CCC GGG TCT AGA GC
3'

SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> SYNTHETIC HUMAN PAPILLOMAVIRUS GENES

<130> 20413Y PCT

<150> 60/150,728

<151> 1999-08-25

<150> 60/210,143

<151> 2000-06-07

<160> 150

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1518

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1

<400> 1

atgagcctgt ggctgcccag cgaggccacc gtgtacctgc ctcccgtgcc cgtgagcaag	60
gtgggtgagca ccgacgagta cgtggcccgcc accaacatct actaccacgc cggcaccagc	120
cgcctgctgg ccgtgggcca cccctacttc cccatcaaga agcccaacaa caacaagatc	180
ctgggtgcca aggtgagcgg cctgcagtac cgcgtgttcc gcatccacct gcccgacccc	240
aacaagttcg gcttccccga cacaagcttc tacaaccccg acaccagcg cctgggtgtgg	300
gcctgcgtgg gcgtggaggt gggccgcggc cagcccctgg gcgtgggcat cagcggccac	360
cccctgctga acaagctgga cgacaccgag aacgccagcg cctacgccgc caacgccggc	420

```

gtggacaacc gcgagtgcac cagcatggac tacaagcaga cccagctgtg cctgatcggc 480
tgcaagcctc ccatcggcga gcactggggc aagggcagcc cctgcaccaa cgtggccgtg 540
aaccccgggc actgccctcc cctggagctg atcaacaccg tgatccagga cggcgacatg 600
gtggacaccg gcttcggcgc catggacttc accaccctgc aggccaacaa gagcgagggtg 660
cccctggaca tctgcaccag catctgcaag taccctgact acatcaagat ggtgagcgag 720
ccctacggcg acagcctgtt cttctacctg cgccgcgagc agatgttcgt gcgccacctg 780
ttcaaccgcg ccggcgccgt gggcgagaac gtgcccagcg acctgtacat caagggcagc 840
ggcagcaccg ccaacctggc cagcagcaac tacttcccca ctcccagcgg cagcatgggtg 900
accagcgacg cccaaatctt caacaagccc tactggctgc agcgcgccca gggccacaac 960
aacggcatct gctggggcaa ccagctgttc gtgaccgtgg tggacaccac ccgcagcacc 1020
aacatgagcc tgtgcgccgc catcagcacc agcgagacca cctacaagaa caccaacttc 1080
aaggagtacc tgcgccacgg cgaggagtac gacctgcagt tcattctcca gctgtgcaag 1140
atcacctga ccgccgacgt gatgacctac atccacagca tgaacagcac catcctggag 1200
gactggaact tcggcctgca gccccctccc ggcggtaccc tggaggacac ctaccgttc 1260
gtgaccagcc aggccatcgc ctgccagaag cacaccctc ccgctcccaa ggaggatccc 1320
ctgaagaagt acaccttctg ggagggtgaa ctgaaggaga agttcagcgc cgacctggac 1380
cagttccccc tgggccgcaa gttcctgctg caggccggcc tgaaggccaa gcccaagttc 1440
accctgggca agcgcaaggc caccctccacc accagcagca ccagcaccac cgccaagcgc 1500
aagaagcgca agctgtaa 1518

```

<210> 2

<211> 1950

<212> DNA

<213> Artificial Sequence

<220>

<223> Mutant, Codon-Optimized HPV16 E1

<400> 2

```

atggccgacc ccgccggcac caacggcgag gagggcaccg gctgcaacgg ctggttctac 60
gtggaggccg tgggtggagaa gaagaccggc gacgccatca gcgacgacga gaacgagaac 120
gacagcgaca ccggcgagga cctggtggac ttcacgtga acgacaacga ctacctgacc 180
caggccgaga ccgagaccgc ccacgccctg ttcaccgccc aggaggccaa gcagcaccgc 240
gacgccgtgc aggtgctgaa gcgcaagtac ctgggcagcc ccctgagcga catcagcggc 300

```

tgcgctcgaca	acaacatcag	ccccgcctg	aaggccatct	gcatcgagaa	gcagagccgc	360
gccgccaagc	gccgcctggt	cgagagcgag	gacagcggct	acggcaacac	cgaggtggag	420
acccagcaga	tgctgcaggt	ggagggccgc	cacgagaccg	agaccccctg	cagccagtac	480
agcggcggca	gcgggcggcg	ctgcagccag	tacagcagcg	gcagcggcgg	cgagggcggtg	540
agcgagcgcc	acaccatctg	ccagaccctt	ctgaccaaca	tcctgaacgt	gctgaagacc	600
agcaacgcca	aggccgccat	gctggccaag	ttcaaggagc	tgtacggcgt	gagcttcagc	660
gagctggtgc	gcccccttcaa	gagcaacaag	agcacctgct	gcgactgggtg	catcgccgcc	720
ttcggcctga	ccccagcat	cgccgacagc	atcaagaccc	tgtgcagca	gtactgcctg	780
tacctgcaca	tccagagcct	ggcctgcagc	tggggcatgg	tggtgctgct	gctggtgcgc	840
tacaagtgcg	gcaagaaccg	cgagaccatc	gagaagctgc	tgagcaagct	gctgtgcgtg	900
agccccatgt	gcatgatgat	cgagcctccc	aagcttcgca	gcaccgccgc	cgccctgtac	960
tggtacaaga	ccggcatcag	caacatcagc	gaggtgtacg	gcgacacccc	cgagtggatc	1020
cagcgccaga	ccgtgctgca	gcacagcttc	aacgactgca	ccttcgagct	gagccagatg	1080
gtgcagtggg	cctacgacaa	cgacatcgtg	gacgacagcg	agatcgccct	caagtacgcc	1140
cagctggccg	acaccaacag	caacgccagc	gccttcctga	agagcaacag	ccaggccaag	1200
atcgtgaagg	actgcgccac	catgtgccgc	cactacaagc	gcgccgagaa	gaagcagatg	1260
agcatgagcc	agtggatcaa	gtaccgctgc	gaccgcgtgg	acgacggcgg	cgaccgcaag	1320
cagatcgtga	tggttcctgcg	ctaccagggc	gtggaattca	tgagcttcct	gaccgccctg	1380
aagcgcttcc	tgcaaggcat	ccccagaag	aactgcatcc	tgctgtacgg	cgccgccaac	1440
accgacaaga	gcctgttcgg	catgagcctg	atgaagttcc	tgcaaggcag	cgtgatctgc	1500
ttcgtgaaca	gcaagagcca	cttctggctg	cagccccctg	ccgacgcca	gatcggcatg	1560
ctggacgacg	ccaccgtgcc	ctgctggaac	tacatcgacg	acaacctgcg	caacgccctg	1620
gacggcaacc	tggtgagcat	ggacgtgaag	caccgcccc	tggtgcagct	gaagtgcctt	1680
cccctgctga	tcaccagcaa	catcaacgcc	ggcaccgaca	gccgctggcc	ctacctgcac	1740
aaccgcctgg	tggtgttcac	cttccccaac	gagttcccc	tcgacgagaa	cggtaacccc	1800
gtgtacgagc	tgaacgacaa	gaactggaag	agcttcttca	gccgcacctg	gagccgcctg	1860
agcctgcacg	aggacgagga	caaggagaac	gacggcgaca	gcctgcccac	cttcaagtgc	1920
gtgagcggcc	agaacaccaa	caccctgtaa				1950

<210> 3

<211> 1098

<212> DNA

<213> Artificial Sequence

<220>

<223> Mutant, Codon-Optimized HPV16 E2

<400> 3

```

atggagaccc tgtgccagcg cctgaacgtg tgccaggaca agatcctgac ccactacgag      60
aacgacagca ccgacctgcg cgaccacatc gactactgga agcacatgcg cctggcctgc      120
gccatctact acaaggcccg cgagatgggc ttcaagcaca tcaaccacca ggtggtgccc      180
accctggccg tgagcaagaa caaggccctg caggccgccc agctgcagct gaccctggag      240
accatctaca acagccagta cagcaacgag aagtggaccc tgcaggacgt gagcctggag      300
gtgtacctga cgcggccccc cggctgcatc aagaagcacg gctacaccgt ggaggtgcag      360
ttcgacggcg acatctgcaa caccatgcac tacaccaact ggaccacat ctacatctgc      420
gaggaggcca gcgtgaccgt ggtggagggg caggtggact actacggcct gtactacgtg      480
cacgagggca tccgcaccta cttcgtgcag ttcaaggacg acgccgagaa gtacagcaag      540
aacaaggtgt gggaggtgca cgccggcggc caggtgatcc tgtgccccac cagcgtgttc      600
agcagcaacg aggtgagcag ccccgagacc atccgccagc acctggccaa ccacagcgcc      660
gccaccacac ccaaggccgt ggccctgggc accgaggaga ccagaccac catccagcgc      720
ccccgcagcg agcccgacac cggcaacccc tgccacacca ccaagctgct gcaccgcgac      780
agcgtggaca gcgcccccat cctgaccgcc ttcaacagca gccacaaggg cgcgatcaac      840
tgcaacagca acaccacccc catcgtgcac ctgaagggcg acgccaacac cctgaagtgc      900
ctgcgctacc gcttcaagaa gcaactgcaag ctgtacaccg ccgtgagcag cacctggcac      960
tggaaccggc acaacgtgaa gcacaagagc gccatcgtga ccctgaccta cgacagcgag     1020
tggcagcgcg accagttcct gagccagggtg aagatcccca agaccatcac cgtgagcacc     1080
ggcttcatga gcatctaa                                     1098

```

<210> 4

<211> 297

<212> DNA

<213> Artificial Sequence

<220>

<223> Mutant, Codon-Optimized HPV16 E7

<400> 4

```

atgcacggcg acacccccac cctgcacgag tacatgctgg acctgcagcc cgagaccacc      60

```

gacctgtacg gctacggcca gctgaacgac agcagcgagg aggaggacga gatcgacggc 120
 cccgccggcc aggccgagcc cgaccgcgcc cactacaaca tcgtgacctt ctgctgcaag 180
 tgcgacagca ccctgcgcct gtgcgtgcag agcaccacag tggacatccg caccctggag 240
 gacctgctga tgggcaccct gggcatcgtg tgccccatct gcagccagaa gccctaa 297

<210> 5

<211> 297

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6a E7

<400> 5

atgcacggcc gccacgtgac cctgaaggac atcgtgctgg acctgcagcc tcccgacccc 60
 gtgggcctgc actgctacga gcagctggtg gacagcagcg aggacgaggt ggacgaggtg 120
 gacggccagg acagccagcc cctgaagcag cacttccaga tcgtgacctg ctgctgcggc 180
 tgcgacagca acgtgcgcct ggtggtgcag tgcaccgaga ccgacatccg cgaggtgcag 240
 cagctcctgc tgggtaccct gaacatcgtg tgccccatct gcgctcccaa gacctaa 297

<210> 6

<211> 318

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E7

<400> 6

atgcacggcc ccaaggccac cctgcaggac atcgtgctgc acctggagcc ccagaacgag 60
 atccccgtgg acctgctgtg ccacgagcag ctgagcgaca gcgaggagga gaacgacgag 120
 atcgacggcg tgaaccacca gcacctgccc gctcgcaggg ccgagcccca gcgccacacc 180
 atgctgtgca tgtgctgcaa gtgcgaggcc cgcacgcagc tgggtggtgga gagcagcgct 240
 gacgacctgc gcgccttcca gcagctgttc ctgaacaccc tgagcttcgt gtgcccctgg 300

tcgccagcc agcagtaa

318

<210> 7

<211> 1107

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6a E2

<400> 7

atggaggcca	tcgccaagcg	cctggacgcc	tgccaggagc	agctgctgga	gctgtacgag	60
gagaacagca	ccgacctgca	caagcacgtg	ctgcactgga	agtgcattgcg	ccacgagagc	120
gtgctgctgt	acaaggccaa	gcagatgggc	ctgagccaca	tcggcatgca	ggtggtgcct	180
cctctgaagg	tgagcgaggc	caagggccac	aacgccatcg	agatgcagat	gcacctcgag	240
agcctgctgc	gcaccgagta	cagcatggag	ccctggaccc	tgccaggagac	cagctacgag	300
atgtggcaga	cccctcccaa	gcgctgcttc	aagaagcgcg	gcaagaccgt	ggaggtgaag	360
ttcgacggct	gcgccaacaa	caccatggac	tacgtggtgt	ggaccgacgt	gtacgtgcag	420
gacaacgaca	cctgggtgaa	ggtgcacagc	atggtggacg	ccaagggcat	ctactacacc	480
tgtggccagt	tcaagacctt	ctacgtgaac	ttcgtgaagg	aggccgagaa	gtacggcagc	540
accaagcact	gggaggtgtg	ctacggcagc	accgtgatct	gcagccccgc	tagcgtgagc	600
agcaccaccc	aggaggtgag	catccccgag	agcaccacct	acactccccgc	ccagaccagc	660
accctggtga	gcagcagcac	caaggaggac	gccgtgcaga	cccctcctcg	caagcgcgcc	720
cgcggcgtgc	agcagagccc	ctgcaacgcc	ctgtgctgtg	cccacatcgg	ccccgtggat	780
agcggcaacc	acaacctgat	caccaacaac	cacgaccagc	accagcgccg	caacaacagc	840
aacagcagcg	ccactcccat	cgtgcagttc	cagggcgaga	gcaactgcct	gaagtgcctc	900
cgctaccgcc	tgaacgatcg	ccaccgccac	ctgttcgacc	tgatcagcag	cacctggcac	960
tgggccagca	gcaaggctcc	ccacaagcac	gccatcgtga	ccgtgacctt	cgacagcgag	1020
gagcagcgcc	agcagttcct	ggacgtggtg	aagatccctc	ccaccatcag	ccacaagctg	1080
ggcttcatga	gcctgcacct	gctgtaa				1107

<210> 8

<211> 1098

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2

<400> 8

atgcagactc ccaaggagac cctgagcgag cgcctgagcg ccctgcagga caagatcatc	60
gaccactacg agaacgacag caaggacatc gacagccaga tccagtactg gcagctgac	120
cgctgggaga acgccatctt cttcgccgct cgcgagcacg ggatccagac cctgaaccac	180
caggtggtgc cgcctacaa catcagcaag agcaaggccc acaaggccat cgagctgcag	240
atggccctgc agggcctggc ccagagcgcc tacaagaccg aggactggac cctgcaggac	300
acctgcgagg agctgtggaa caccgagccc acccactgct tcaagaaggg aggccagacc	360
gtgcaggtgt acttcgacgg caacaaggac aactgcatga actacgtggc ctgggacagc	420
gtgtactaca tgaccgacgc cggcacctgg gacaagaccg ccacctgcgt gagccaccgc	480
ggcctgtact acgtgaagga gggctacaac accttctaca tcgagttcaa gagcgagtgc	540
gagaagtacg gcaacaccgg cacctgggag gtgcacttcg gcaacaacgt gatcgactgc	600
aacgacagca tgtgcagcac cagcgacgac accgtgagcg ccaccagct ggtgaagcag	660
ctgcagcaca ctcccagccc ctacagcagc accgtgagcg tgggcaccgc caagacctac	720
ggccagacca gcgccgccac tcgccctggc cactgcgggc tggccgagaa gcagcactgc	780
gggcccgtga accctctgct gggcgccgcc accgccaccg gcaacaacaa gcgccgcaag	840
ctgtgcagcg gcaacaccac tcccatcatc cacctgaagg gcgaccgcaa cagcctgaag	900
tgcttgcggt accgcctgcg caagcacagc gaccactacc gcgacatcag cagcacctgg	960
cactggaccg gcgccgggaa cgagaagacc ggcatacctga ccgtgacctc ccacagcgag	1020
accagcgca ccaagttcct gaacaccgtg gccatccccg acagcgtgca gatcctggtg	1080
ggctacatga ccatgtaa	1098

<210> 9

<211> 129

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 9

atgagcctgt ggctgcccag cgaggccacc gtgtacctgc ctcccgtgcc cgtgagcaag	60
gtggtgagca ccgacgagta cgtggcccgcc accaacaatct actaccacgc cggcaccagc	120
cgcttctctg	129

<210> 10

<211> 129

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 10

cgcattccacc tgcccagacc caacaagtgc ggcttccccg acacaagctt ctacaacccc	60
gacaccacgc gcctggtgtg ggcttgcgtg ggcgtggagg tgggccgcgc ccagcccctg	120
ggcgtgggc	129

<210> 11

<211> 129

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 11

gagtgcattc gcatggacta caagcagacc cagctgtgcc tgatcggtgc caagcctccc	60
atcggcgagc actggggcaa gggcagcccc tgcaccaacg tggccgtgaa ccccggcgac	120
tgcctccc	129

<210> 12

<211> 132

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 12

gccacaaga gcgagggtgcc cctggacatc tgcaccagca tctgcaagta ccccgactac	60
atcaagatgg tgagcgagcc ctacggcgac agcctgttct tctacctgcg ccgcgagcag	120
atgttcgtgc gc	132

<210> 13

<211> 129

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 13

gccagcagca actacttccc cactcccagc ggagcatgg tgaccagcga cgcccaaadc	60
ttcaacaagc cctactggct gcagcgcgcc cagggccaca acaacggcat ctgctggggc	120
aaccagctg	129

<210> 14

<211> 135

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 14

gagtacctgc gccacggcga ggagtacgac ctgcagttca tcttccagct gtgcaagatc	60
accctgaccg ccgacgtgat gacctacatc cacagcatga acagcaccat cctggaggac	120

tggaacttcg gcctg

135

<210> 15

<211> 135

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 15

gctcccaagg aggatcccct gaagaagtac accttctggg aggtgaacct gaaggagaag	60
ttcagcgccg acctggacca gttccccctg ggccgcaagt tcctgctgca ggccggcctg	120
aaggccaagc ccaag	135

<210> 16

<211> 135

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 16

gttggggtcg ggcaggtgga tgcggaacac gcggtactgc aggccgctca ccttgggcac	60
caggatcttg ttgttggttg gcttcttgat ggggaagtag ggggtggccca cggccagcag	120
gcggctggtg ccggc	135

<210> 17

<211> 132

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 17

```

cttgtagtcc atgctgatgc actcgcggtt gtccacgccg gcgttggcgg cgtaggcgct      60
ggcgttctcg gtgtcgcca gcttggtcag cagggggtgg ccgctgatgc ccacgccag      120
gggctggccg cg                                     132

```

<210> 18

<211> 129

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 18

```

caggggcacc tcgctcttgt tggcctgcag ggtggtgaag tccatggcgc cgaagccggt      60
gtccaccatg tcgccgtcct ggatcacggt gttgatcagc tccaggggag ggcagtcgcc      120
ggggttcac                                     129

```

<210> 19

<211> 132

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 19

```

gggagtgggg aagtagttgc tgctggccag gttggcgggt ctgccgtgc ccttgatgta      60
caggtcgtcg ggcacgttct cgccacggc gccggcgcggt ttgaacaggt ggcgcacgaa      120
catctgctcg cg                                     132

```

<210> 20

<211> 144

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 20

ctcctcgccg tggcgcaggt actccttgaa gttggtgttc ttgtaggtgg tctcgctggt	60
gctgatggcg gcgcacaggc tcatgttggt gctgcgggtg gtgtccacca cggtcacgaa	120
cagctggttg ccccagcaga tgcc	144

<210> 21

<211> 132

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 21

cttcagggga tcctccttgg gagcgggagg ggtgtgcttc tggcaggcga tggcctggct	60
ggtcacgaag cggtaggtgt cctccagggt accgccggga gggggctgca ggccgaagtt	120
ccagtccctcc ag	132

<210> 22

<211> 123

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 22

cactagagat ctgaattctt acagcttgcg cttcttgcg c ttggcggtgg tgctgggtgct 60
 gctgggtgggtg ggggtggcct tgcgcttgcc cagggtgaac ttgggccttg ccttcaggcc 120
 ggc 123

<210> 23

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 23

cgcggccagc ccctgggcgt g 21

<210> 24

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 24

gcccacgccc aggggctggc cgcg 24

<210> 25

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 25

gccaacaaga gcgaggtgcc c

21

<210> 26

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 26

caggggcacc tcgctcttgt tggc

24

<210> 27

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 27

gccagcagca actacttccc cac

23

<210> 28

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 28

gggagtgggg aagtagttgc tgc 23

<210> 29

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 29

ctggaggact ggaacttcgg cctg 24

<210> 30

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 30

caggccgaag ttccagtcct ccag 24

<210> 31

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 31

cactagagat ctgaattcctt acagc 25

<210> 32

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 L1 fragment

<400> 32

catctcagat ctgccacat gacgctgtgg ctgcccag

38

<210> 33

<211> 129

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 33

atggccgacc cgcgccgcac caacggcgag gagggcaccg gctgcaacgg ctggttctac 60

gtggaggccg tgggtggagaa gaagaccggc gacgccatca gcgacgacga gaacgagaac 120

gacagcgac 129

<210> 34

<211> 132

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 34

```

gtgctgcttg gcctcctggg cgggtgaacag ggcgtgggcg gtctcgggtct cggcctgggt      60
caggtagtcg ttgtcgttca cgatgaagtc caccagggtcc tcgccgggtgt cgctgtcgtt      120
ctcgttctcg tc                                          132

```

<210> 35

<211> 132

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 35

```

gcccaggagg ccaagcagca ccgcgacgcc gtgcagggtgc tgaagcgcaa gtacctgggc      60
agccccctga gcgacatcag cggctgcgctc gacaacaaca tcagcccccg cctgaaggcc      120
atctgcatcg ag                                          132

```

<210> 36

<211> 131

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 36

```

ctcgtggcgg ccctccacct gcagcatctg ctgggtctcc acctcgggtgt tgccgtagcc      60
gctgtcctcg ctctcgaaca ggcggcgctt ggcggcgcggt ctctgcttct cgatgcagat      120
ggccttcagg c                                          131

```

<210> 37

<211> 132

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 37

caggtggagg gccgccacga gaccgagacc ccctgcagcc agtacagcgg cggcagcggc	60
ggcggctgca gccagtacag cagcggcagc ggcggcgagg gcgtgagcga gcgccacacc	120
atctgccaga cc	132

<210> 38

<211> 135

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 38

cttgaagggg cgcaccagct cgctgaagct cacgccgtac agtccttga acttggccag	60
catggcggcc ttggcggtgc tggctcttcag cacgttcagg atgttggtca gaggggtctg	120
gcagatggtg tggcg	135

<210> 39

<211> 135

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 39

gagctggtgc gccccttcaa gagcaacaag agcacctgct gcgactggtg catcgccgcc	60
ttcggcctga cccccagcat cgccgacagc atcaagacct tgctgcagca gtactgcctg	120
tacctgcaca tccag	135

<210> 40

<211> 136

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 40

catgggggctc acgcacagca gcttgctcag cagcttctcg atggtctcgc ggttcttgcc	60
gcacttgtag cgcaccagca gcagcaccac catgccccag ctgcaggcca ggctctggat	120
gtgcaggtac aggcat	136

<210> 41

<211> 132

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 41

ctgctgtgctg tgagccccat gtgcatgatg atcgagcctc ccaagcttcg cagcaccgcc	60
gccgccctgt actggtacaa gaccggcatc agcaacatca gcgaggtgta cggcgacacc	120
cccgagtgga tc	132

<210> 42

<211> 129

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 42

```

ggcgatctcg ctgtcgcca cgatgtcggt gtcgtaggcc cactgcacca tctggctcag      60
ctcgaagggtg cagtcgttga agctgtgctg cagcacggtc tggcgctgga tccactcggg    120
ggtgtcgcc                                     129

```

<210> 43

<211> 129

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 43

```

gtggacgaca gcgagatcgc ctacaagtac gccagctgg ccgacaccaa cagcaacgcc      60
agcgcccttc tgaagagcaa cagccaggcc aagatcgtga aggactgcgc caccatgtgc    120
cgccactac                                     129

```

<210> 44

<211> 129

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 44

```

gtagcgcagg aacatcacga tctgcttgcg gtcgccgccg tcgtccacgc ggtcgcagcg      60
gtacttgatc cactgggtca tgctcatctg cttcttctcg gcgcgcttgt agtggcggca    120
catggtggc                                     129

```

<210> 45

<211> 129

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 45

cagatcgtga tgttcctgcg ctaccagggc gtggaattca tgagcttcct gaccgccctg	60
aagcgcttcc tgcagggcat cccaagaag aactgcatcc tgctgtacgg cgccgccaac	120
accgacaag	129

<210> 46

<211> 130

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 46

gccgatcttg gcgtcggcca ggggctgcag ccagaagtgg ctcttgctgt tcacgaagca	60
gatcacgctg ccctgcagga acttcatcag gctcatgccg aacaggctct tgtcggtggt	120
ggcggcgccg	130

<210> 47

<211> 129

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 47

ctggccgacg ccaagatcgg catgctggac gacgccaccg tgccctgctg gaactacatc	60
---	----

gacgacaacc tgcgcaacgc cctggacggc aacctggtga gcatggacgt gaagcaccgc 120
cccctggtg 129

<210> 48

<211> 132

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 48

gaactcgttg gggaaggtga acaccaccag gcggttgtgc aggtagggcc agcggctgtc 60
ggtgccggcg ttgatgttgc tggatgacag caggggaggg cacttcagct gcaccagggg 120
gcggtgcttc ac 132

<210> 49

<211> 126

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 49

gtgttcacct tccccaacga gttccccttc gacgagaacg gtaaccccggt gtacgagctg 60
aacgacaaga actggaagag cttcttcagc cgcacctgga gccgcctgag cctgcacgag 120
gacgag 126

<210> 50

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 50

catgagagat ctttacaggg tgttggtggt ctggccgctc acgcacttga aggtgggcag 60
gctgtcgccg tcgttctcct tgtcctcgtc ctcgtgcagg ctcag 105

<210> 51

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 51

gcctgaaggc catctgcac gag 23

<210> 52

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 52

ctcgatgcag atggccttca ggc 23

<210> 53

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 53

gagctggtgc gccccttcaa g

21

<210> 54

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 54

cttgaagggg cgcaccagct c

21

<210> 55

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 55

ctgctgtgcg tgagcccat g

21

<210> 56

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 56

catggggctc acgcacagca g

21

<210> 57

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 57

gccaccatgt gccgccacta c

21

<210> 58

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 58

gtagtggcgg cacatggtgg c

21

<210> 59

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 59

ctggccgacg ccaagatcgg c

21

<210> 60

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 60

gccgatcttg gcgtcggcca g

21

<210> 61

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 61

gtgttcacct tccccaacga gttc

24

<210> 62

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 62

gaactcgttg gggaaggtga acac

24

<210> 63

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 63

catgagagat ctttacaggg tgttg

25

<210> 64

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E1 fragment

<400> 64

catctcagat ctgccaccat ggccgacccc gccggcac

38

<210> 65

<211> 99

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 65

atggagaccc tgtgccagcg cctgaacgtg tgccaggaca agatcctgac ccactacgag 60
aacgacagca ccgacctgcg cgaccacatc gactactgg 99

<210> 66

<211> 104

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 66

ccaccaggtg gtgcccaccc tggccgtgag caagaacaag gccctgcagg ccgccgagct 60
gcagctgacc ctggagacga tctacaacag ccagtacagc aacg 104

<210> 67

<211> 108

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 67

ccggctgcat caagaagcac ggctacaccg tggaggtgca gttcgacggc gacatctgca 60
acaccatgca ctacaccaac tggacccaca ttacatctg tgaggagg 108

<210> 68

<211> 104

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 68

cgtgcacgag gggatccgca cctacttcgt gcagttcaag gacgacgccg agaagtacag 60
caagaacaag gtgtgggagg tgcacgccgg aggccagggtg atcc 104

<210> 69

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 69

ggccaaccac agcgccgcca cccacaccaa ggccgtggcc ctgggcaccg aggagaccca 60
gaccacaatc cagcgccctc gcagcgagcc cgacaccggc aaccctgcc 110

<210> 70

<211> 107

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 70

gccacaaggg ccgatcaac tgcaacagca acaccacccc ttcgtgcac ctgaagggcg 60
acgccaacac cctgaagtgc ctgcggtacc gcttcaagaa gcactgc 107

<210> 71

<211> 113

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 71

ccaggggtggg caccacctgg tgggtgatgt gcttgaagcc catctcgcg gccttgtagt 60
 agatggcgca ggccaggcgc atgtgcttcc agtagtcgat gtggtcgcgc agg 113

<210> 72

<211> 101

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 72

gccgtgcttc ttgatgcagc cggtaggggc ggtcaggtac acctccaggc tcacgtcctg 60
 caggggtccac ttctcgttgc tgtactggct gttgtagatc g 101

<210> 73

<211> 98

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 73

ggtgcggatc ccctcgtgca cgtagtacag gccgtagtag tccacctggc cctccaccac 60
 ggtcacgctg gcctcctcac agatgtaaat gtgggtcc 98

<210> 74

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 74

```
gggtggcggc gctgtggtg gccaggtgct ggcggatcgt ctcggggctg ctcacctcgt      60
tgctgctgaa cacgctggtg gggcacagga tcacctggcc tccggcgtgc      110
```

<210> 75

<211> 111

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 75

```
gcagttgatc cggcccttgt ggctgctgtt gaaggcggtc aggatagggg cgctgtcgac      60
gctgtcgcgg tgcagcagct tgggtggtgtg gcagggggtg ccggtgtcgg g      111
```

<210> 76

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 76

```
cgtaggtcag ggtcacgata gcgctcttgt gcttcacgtt gtggccggtc cagtgccagg      60
tgctgctcac ggcggtgtac agcttgacgt gcttcttgaa gcggtaccgc      110
```

<210> 77

<211> 111

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 77

tttagatgct catgaagccg gtgctcacgg tgatgggtctt ggggatcttc acctgggtca 60
ggaactggtc gcgctgccac tcgctgtcgt aggtcagggg caccgatagcg c 111

<210> 78

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 78

cgagctgata tcgaattcag atctgccacc atggagaccc tgtgccagcg 50

<210> 79

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 79

ggttgcagat ctagactcga gtttagatgc tcatgaagcc ggtgc 45

<210> 80

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 80

ccggctgcat caagaagcac g

21

<210> 81

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 81

ggccaaccac agcgccgcc

19

<210> 82

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 82

gccgtgcttc ttgatgcagc c

21

<210> 83

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 83

gggtggcggc gctgtgg

17

<210> 84

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E2 fragment

<400> 84

cgtaggtcag ggtcacgata gc

22

<210> 85

<211> 109

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E7 fragment

<400> 85

ggccggagat ctgatatcga attcgccacc atgcacggcg acacccccac cctgcacgag

60

tacatgctgg acctgcagcc cgagaccacc gacctgtacg gctacggcc

109

<210> 86

<211> 106

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E7 fragment

<400> 86

gccgagcccg accgcgccca ctacaacatc gtgaccttct gctgcaagtg cgacagcacc	60
ctgcgcctgt gcgtgcagag caccacgctc gacatccgca ccctgg	106

<210> 87

<211> 96

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E7 fragment

<400> 87

gggcgcgggc gggctcggcc tggccggcgg ggccgtcgat ctcgctctct tcctcgctgc	60
tgctcgttcag ctggccgtag ccgtacaggt cgggtgg	96

<210> 88

<211> 106

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E7 fragment

<400> 88

ccgcggcaga tctagactcg agtttagggc ttctggctgc agattgggca cacgattccc	60
agggtgccca tcagcaggtc ctccaggggtg cggatgtcga cgtggg	106

<210> 89

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E7 fragment

<400> 89

ggccggagat ctgatatcga attcg

25

<210> 90

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV16 E7 fragment

<400> 90

ccgcggcaga tctagactcg

20

<210> 91

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6a E7 fragment

<400> 91

gtcacagatc tgatatcgaa ttccaccatg cacggccgcc acgtgaccct gaaggacatc

60

gtgctggacc tgcagcctcc cgaccccgctg ggctgcact gctac

105

<210> 92

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6a E7 fragment

<400> 92

ctggaagtgc tgcttcaggg gctggctgtc ctggccgtcc acctcgtcca cctcgtcctc 60
gctgctgtcc accagctgct cgtagcagtg caggcccacg gggtc 105

<210> 93

<211> 107

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6a E7 fragment

<400> 93

ccagcccctg aagcagcact tccagatcgt gacctgctgc tgcggctgcg acagcaacgt 60
gcgcttggtg gtgcagtgca ccgagaccga catccgcgag gtgcagc 107

<210> 94

<211> 102

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6a E7 fragment

<400> 94

cagtcagatc tagagatatc tttaggtctt gggagcgcag atggggcaca cgatgttcag 60

ggtaccacagc aggagctgct gcacctcgcg gatgtcggtc tc 102

<210> 95

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 95

gtcacagatc tgatatcgaa ttcc 24

<210> 96

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 96

cagtcagatc tagagatatc tttagg 26

<210> 97

<211> 109

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E7 fragment

<400> 97

gtcacagatc tgatatcgaa ttccaccatg cacggcccca aggccaccct gcaggacatc 60

gtgctgcacc tggagcccca gaacgagatc cccgtggacc tgctgtgcc 109

<210> 98

<211> 111

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E7 fragment

<400> 98

gggctcggcc ctgcgagcgg gcaggtgctg gtggttcacg ccgtcgatct cgtcgttctc 60

ctcctcgctg tcgctcagct gtcctgtggca cagcaggtcc acggggatct c 111

<210> 99

<211> 108

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E7 fragment

<400> 99

gcccgcctgc agggccgagc cccagcgcca caccatgctg tgcattgtgct gcaagtgcga 60

ggcccgcctc gagctggtgg tggagagcag cgctgacgac ctgcgcgc 108

<210> 100

<211> 109

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E7 fragment

<400> 100

cagtcagatc tagagatatc tttactgctg gctggcgcac caggggcaca cgaagctcag 60
ggtgttcagg aacagctgct ggaaggcgcg caggtcgtca gcgctgctc 109

<210> 101

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Fragment

<400> 101

gtcacagatc tgatatcgaa ttccac 26

<210> 102

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Fragment

<400> 102

cagtcagatc tagagatatc tttactg 27

<210> 103

<211> 90

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 103

gaattcagat ctgatatcac catggaggcc atcgccaagc gcctggacgc ctgccaggag 60
 cagctgctgg agctgtacga ggagaacagc 90

<210> 104

<211> 92

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 104

ccttgtagag cagcacgctc tcgtggcgca tgcacttcca gtgcagcacg tgcttgtagca 60
 ggtcggtagct gttctcctcg tacagctcca gc 92

<210> 105

<211> 96

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 105

ccacgagagc gtgctgctgt acaaggccaa gcagatgggc ctgagccaca tcggcatgca 60
 ggtggtgcct cctctgaagg tgagcgaggg caaggg 96

<210> 106

<211> 103

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 106

gcagggtcca gggctccatg ctgtactcgg tgcgcagcag gctctcgagg tgcattctgca 60
tctcgatggc gttgtggccc ttggcctcgc tcaccttcag agg 103

<210> 107

<211> 98

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 107

cgagtacagc atggagccct ggaccctgca ggagaccagc tacgagatgt ggcagacccc 60
tcccaagcgc tgcttcaaga agcgcggcaa gaccgtgg 98

<210> 108

<211> 102

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 108

cgttgtcctg cacgtacagc tcggtccaca ccacgtagtc catggtgttg ttggcgcagc 60
cgtcgaactt cacctccacg gtcttgccgc gcttcttgaa gc 102

<210> 109

<211> 102

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 109

```

ccgacgtgta cgtgcaggac aacgacacct ggggtgaaggt gcacagcatg gtggacgcca      60
agggcatcta ctacacctgt ggccagttca agacctacta cg                          102

```

<210> 110

<211> 92

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 110

```

gctgccgtag cacacctccc agtgcttggt gctgccgtac ttctcggcct ccttcacgaa      60
gttcacgtag taggtcttga actggccaca gg                                    92

```

<210> 111

<211> 94

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 111

```

gcactgggag gtgtgctacg gcagcaccgt gatctgcagc cccgctagcg tgagcagcac      60
cacccaggag gtgagcatcc ccgagagcac cacc                                    94

```

<210> 112

<211> 97

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 112

gcgaggaggg gtctgcacgg cgtcctcctt ggtgctgctg ctcaccaggg tgctggtctg 60

ggcgggagtg taggtggtgc tctcggggat gtcacc 97

<210> 113

<211> 97

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 113

ggacgccgtg cagacccctc ctcgcaagcg cgcccgcggc gtgcagcaga gcccctgcaa 60

cgccctgtgc gtggcccaca tcggccccgt ggacagc 97

<210> 114

<211> 94

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 114

ggcgctgctg ttgctgttgt tgcggcgctg gtgctggctg tggttgttgg tgatcaggtt 60

gtggttgccg ctgtccacgg ggccgatgtg ggcc 94

<210> 115

<211> 95

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 115

ccgcaacaac agcaacagca gcgccactcc catcgtgcag ttccagggcg agagcaactg	60
cctgaagtgc ttccgctacc gcctgaacga tcgcc	95

<210> 116

<211> 96

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 116

cgtgcttggtg gggagccttg ctgctggccc agtgccaggt gctgctgac aggtcgaaca	60
ggtggcggtg gcgatcggtc aggcggtagc ggaagc	96

<210> 117

<211> 95

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 117

gcagcaaggc tccccacaag cagccatcg tgaccgtgac ctacgacagc gaggagcagc	60
--	----

gccagcagtt cctggacgtg gtgaagatcc ctccc

95

<210> 118

<211> 96

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 118

ctcgagagat ctcccggtc tagagcttac agcaggtgca ggctcatgaa gccagcttg

60

tggctgatgg tgggaggat cttcaccacg tccagg

96

<210> 119

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 119

gaattcagat ctgatatcac catgg

25

<210> 120

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 120

gcaggggtcca gggctccatg c 21

<210> 121

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 121

cgagtacagc atggagccct ggacc 25

<210> 122

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 122

gctgccgtag cacacctccc agtgc 25

<210> 123

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 123

gcactgggag gtgtgctacg g 21

<210> 124

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 124

ggcgctgctg ttgctgttgt tgc

23

<210> 125

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 125

ccgcaacaac agcaacagca gc

22

<210> 126

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV6 E2 fragment

<400> 126

ctcgagagat ctcccgggtc tagagc

26

<210> 127

<211> 97

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 127

gaattcagat ctgatatcac catgcagact cccaaggaga ccctgagcga ggcgctgagc	60
gccctgcagg acaagatcat cgaccactac gagaacg	97

<210> 128

<211> 98

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 128

cgaagaagat ggcgttctcc cagcggatca gctgccagta ctggatctgg ctgtcgatgt	60
ccttgctgtc gttctcgtag tggtcgatga tcttgctc	98

<210> 129

<211> 94

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 129

ccgctgggag aacgccatct tcttcgccgc tcgcgagcac gggatccaga ccctgaacca	60
---	----

ccagggtggtg cccgcctaca acatcagcaa gagc

94

<210> 130

<211> 94

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 130

cctcgggtctt gtaggcgctc tgggccaggc cctgcagggc catctgcagc tcgatggcct 60

tgtgggcctt gctcttgctg atgttgtagg cggg 94

<210> 131

<211> 91

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 131

cccagagcgc ctacaagacc gaggactgga ccctgcagga cacctgagag gagctgtgga 60

acaccgagcc caccactgc ttcaagaagg g 91

<210> 132

<211> 94

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 132

gctgtcccag gccacgtagt tcatgcagtt gtccttggtg ccgtcgaagt acacctgcac 60

ggctctggcct cccttcttga agcagtgggt gggc 94

<210> 133

<211> 90

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 133

gcatgaacta cgtggcctgg gacagcgtgt actacatgac cgacgccggc acctgggaca 60

agaccgccac ctgcgtgagc caccgcggcc 90

<210> 134

<211> 92

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 134

ccgtacttct cgcactcgct cttgaactcg atgtagaagg tgttgtagcc ctccttcacg 60

tagtacaggc cgcggtggct cagcaggtg gc 92

<210> 135

<211> 94

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 135

cgagttcaag agcgagtgcg agaagtacgg caacaccggc acctgggagg tgcacttcgg 60
caacaacgtg atcgactgca acgacagcat gtgc 94

<210> 136

<211> 100

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 136

gctgtagggg ctgggagtgt gctgcagctg cttcaccagc tgggtggcgc tcacggtgtc 60
gtcgctggtg ctgcacatgc tgctgttgca gtcgatcacg 100

<210> 137

<211> 93

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 137

gcacactccc agcccctaca gcagcaccgt gagcgtgggc accgccaaga cctacggcca 60
gaccagcgcc gccactcgcc ctggccactg cgg 93

<210> 138

<211> 96

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 138

gcttgttggt gccggtggcg gtggcggcgc ccagcagagg gttcacgggc ccgcagtgct 60

gcttctcggc caggccgcag tggccagggc gagtgg 96

<210> 139

<211> 97

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 139

gccaccgcca ccggcaacaa caagcgccgc aagctgtgca gcggcaacac cactcccatc 60

atccacctga agggcgaccg caacagcctg aagtggc 97

<210> 140

<211> 97

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 140

ggcgccggtc cagtgccagg tgctgctgat gtcgcggtag tggtcgctgt gcttgccgag 60

gcggtaccgc aggcaattca ggctgttgcg gtcgcc 97

<210> 141

<211> 99

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 141

gcacctggca ctggaccggc gccgggaacg agaagaccgg catcctgacc gtgacctacc	60
acagcgagac ccagcgcacc aagttcctga acaccgtgg	99

<210> 142

<211> 98

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 142

ctcgagagat ctcccgggtc tagagcttac atggatcatgt agcccaccag gatctgcacg	60
ctgtcgggga tggccacggt gttcaggaac ttggtgcg	98

<210> 143

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 143

gaattcagat ctgatatcac catgc	25
-----------------------------	----

<210> 144

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 144

cctcgggtctt gtaggcgctc tgg

23

<210> 145

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 145

cccagagcgc ctacaagacc g

21

<210> 146

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 146

ccgtacttct cgcactcgct c

21

<210> 147

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 147

cgagttcaag agcgagtgcg

20

<210> 148

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 148

gcttggtggt gccggtggcg g

21

<210> 149

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 149

gccaccgcca ccggcaacaa caagc

25

<210> 150

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Codon-Optimized HPV18 E2 fragment

<400> 150

ctcgagagat ctcccggggtc tagagc

26

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number
WO 01/14416 A3

(51) International Patent Classification⁷: **C07K 14/025**,
C12N 15/861, 5/10

(21) International Application Number: PCT/US00/22932

(22) International Filing Date: 21 August 2000 (21.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/150,728 25 August 1999 (25.08.1999) US
60/210,143 7 June 2000 (07.06.2000) US

(71) Applicant (*for all designated States except US*): **MERCK & CO., INC.** [US/US]: 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **NEEPER, Michael, P.** [US/US]: 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **MCCLEMENTS, William, L.**

[US/US]: 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **JANSEN, Kathrin, U.** [DE/US]: 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **SCHULTZ, Loren, D.** [US/US]: 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **CHEN, Ling** [US/US]: 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **WANG, Xin-Min** [CN/US]: 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(74) Common Representative: **MERCK & CO., INC.**: 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).


(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: **SYNTHETIC PAPILLOMAVIRUS GENES OPTIMIZED FOR EXPRESSION IN HUMAN CELLS**

Comparison of protein expression of native and synthetic HPV16 L1 genes



(57) Abstract: Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.



IT, LU, MC, NL, PT, SE). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
6 December 2001

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/22932

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/025 C12N15/861 C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, SCISEARCH, MEDLINE, EMBASE, BIOTECHNOLOGY ABS, CHEM ABS Data, EMBL, GENSEQ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ZHOU JIAN ET AL: "Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability." JOURNAL OF VIROLOGY, vol. 73, no. 6, June 1999 (1999-06), pages 4972-4982, XP002164427 ISSN: 0022-538X page 4973, right-hand column, paragraphs 2-4 page 4976, left-hand column, paragraph 3 -page 4978, left-hand column, paragraph 2 figure 1; table 1 ---	1-25,30
Y	US 5 679 509 A (WHEELER COSETTE M ET AL) 21 October 1997 (1997-10-21) figures 2,3 --- -/--	1-18,30

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

2 April 2001

Date of mailing of the international search report

18/04/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

ALCONADA RODRIG..., A

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/US 00/22932

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 39178 A (UNIV PENNSYLVANIA ;WISTAR INST (US); WILSON JAMES M (US); ERTL HIL) 12 December 1996 (1996-12-12) page 15, line 24 -page 16, line 5 claims 1,5,7,14	19-21,25
Y	AFGHAN R K ET AL: "Immune responses induced by vaccination with plasmid DNA containing the HPV16 E7 ORF." IMMUNOLOGY, vol. 95, no. SUPPL. 1, December 1998 (1998-12), page 106 XP000982724 6th Annual Congress of the British Society for Immunology;Harrogate, England, UK; December 1-4, 1998 ISSN: 0019-2805 abstract	22
Y	KOTECHA M T ET AL: "Humoral responses induced by vaccination with plasmid DNA containing the HPV16 L1 ORF." IMMUNOLOGY, vol. 95, no. SUPPL. 1, December 1998 (1998-12), page 107 XP000982725 6th Annual Congress of the British Society for Immunology;Harrogate, England, UK; December 1-4, 1998 ISSN: 0019-2805 abstract	22
Y	WO 96 00583 A (DONNELLY JOHN J ;LIU MARGARET A (US); MERCK & CO INC (US); MARTINE) 11 January 1996 (1996-01-11) page 15, line 30 -page 16, line 27 examples 5-7	22-24
Y	XU JIANQING ET AL: "Human papillomavirus 16 E7-specific CTL induction through mouse B7-1 costimulating with E7C subgene." ZHONGHUA WEISHENGWUXUE HE MIANYIXUE ZAZHI, vol. 19, no. 3, May 1999 (1999-05), pages 227-231, XP000989739 ISSN: 0254-5101 abstract	22,24

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/22932

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>SMAHEL MICHAL ET AL: "DNA vaccine against oncogenic hamster cells transformed by HPV16 E6/E7 oncogenes and the activated ras oncogene." ONCOLOGY REPORTS, vol. 6, no. 1, January 1999 (1999-01), pages 211-215, XP000989763 ISSN: 1021-335X the whole document</p>	22,24
A	<p>--- NIMAKO MERCY ET AL: "Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III." CANCER RESEARCH, vol. 57, no. 21, 1 November 1997 (1997-11-01), pages 4855-4861, XP000982722 ISSN: 0008-5472 page 4856, right-hand column, paragraph 3 -page 4857, left-hand column, paragraph 1; figures 1,2</p>	19,20
A	<p>--- BORYSIEWICZ L K ET AL: "A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer." LANCET (NORTH AMERICAN EDITION), vol. 347, no. 9014, 1996, pages 1523-1527, XP000997454 ISSN: 0099-5355 the whole document</p>	26-29
A	<p>--- TOES RENE E M ET AL: "Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 26, 23 December 1997 (1997-12-23), pages 14660-14665, XP002164428 Dec. 23, 1997 ISSN: 0027-8424 the whole document</p> <p style="text-align: center;">--- -/--</p>	19-21, 24-29

INTERNATIONAL SEARCH REPORT

Intern. Patent Application No

PCT/US 00/22932

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	HE Z ET AL: "Viral recombinant vaccines to the E6 and E7 antigens of HPV-16." VIROLOGY, vol. 270, no. 1, 25 April 2000 (2000-04-25), pages 146-161, XP000989692 ISSN: 0042-6822 figures 2,3 see Section: "Expression systems for E6 and E7 of HPV-16" on page 156 ---	19-29
T	CHEN CHIEN-HUNG ET AL: "Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines." VACCINE, vol. 18, no. 19, 3 April 2000 (2000-04-03), pages 2015-2022, XP004202497 ISSN: 0264-410X the whole document -----	19-29

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-18 relate to several human HPV16 papillomavirus polypeptides defined by reference to a desirable characteristic or property, namely, that they have reduced protein function, that they maintain the immunogenicity and that they contain codons optimized for expression in a human host.

The claims cover all HPV16 papillomavirus having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such polypeptides, namely the variant HPV16 L1 polypeptide (SEQ ID NO: 1), the variant HPV16 E1 polypeptide (SEQ ID NO:2), the variant HPV16 E2 polypeptide (SEQ ID NO:3) and the variant HPV16 E7 polypeptide (SEQ ID NO:4). In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the polypeptides by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the HPV16 L1, E1, E2 and E7 polypeptides (SEQ ID NOs: 1, 2, 3 and 4 respectively).

Present claims 29-30 relate to a several plasmid and viral papillomavirus vaccines defined by reference to a desirable characteristic or property, namely, that they comprise an L1, E1, E2 or E7 HPV polynucleotide whose codons have been optimized for expression in a human host cells.

The claims cover all polynucleotide vaccines having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such polynucleotide vaccines. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product/compound/method/apparatus by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the polynucleotide vaccines comprising the HPV16 L1, E1, E2 and E7 variant polypeptides of SEQ ID NO:1, 2, 3 and 4, respectively.

Present claim 30 relates to a method of making recombinant HPV protein in a host cell which is defined by reference to a desirable characteristic or property, namely, that the host cells express a human papillomavirus protein having reduced protein function, maintaining its immunogenicity and containing codons optimized for expression in a human host. The claims cover all methods for recombinant expression of HPV16 papillomavirus proteins having this characteristic or property, whereas

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the method by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those methods relating to the recombinant expression of the HPV16 L1, E1, E2 and E7 polypeptides (SEQ ID NOs: 1, 2, 3 and 4 respectively).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No

PCT/US 00/22932

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5679509 A	21-10-1997	NONE	
WO 9639178 A	12-12-1996	US 5698202 A AU 6261696 A US 6019978 A	16-12-1997 24-12-1996 01-02-2000
WO 9600583 A	11-01-1996	AU 701973 B AU 2694595 A CN 1156966 A CZ 9603752 A EP 0768893 A FI 965224 A HU 76446 A JP 10501987 T NO 965590 A NZ 288045 A PL 317874 A SK 164196 A US 5866553 A ZA 9504641 A	11-02-1999 25-01-1996 13-08-1997 13-08-1997 23-04-1997 27-12-1996 29-09-1997 24-02-1998 28-02-1997 26-08-1998 28-04-1997 06-08-1997 02-02-1999 26-01-1996